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Inflammatory bowel disease (IBD) results from a dysregulated interaction 
between the microbiota and a genetically susceptible host.  Genetic studies 
have linked TNFSF15 polymorphisms and its protein TNF-like ligand 1A 
(TL1A) with IBD, but the functional role of TL1A in linking tissue homeostasis 
and intestinal inflammation is not known. Here, using cell-specific genetic 
deletion models, we report an essential role for CX3CR1+ mononuclear 
phagocyte (MNP) TL1A in signaling through its cognate receptor death 
receptor 3 (DR3) on group 3 innate lymphoid cell (ILC3) to promote IL-22 
dependent protection during acute colitis. Induction of intestinal MNP TL1A by 
IBD-associated adherent microbes confers TL1A-dependent protection from 
acute colitis.  However, in contrast to this protective role in acute colitis, colitis-
induced DR3-dependent expression of OX40L enables MHCII+ ILC3 to co-
stimulate antigen-specific T cell proliferation and exacerbate chronic T cell-
dependent colitis. Colonic biopsies from IBD patients revealed increased TL1A 
expression on MNPs and OX40L on ILC3 compared to healthy controls, 
highlighting the conserved TL1A-OX40L ILC3 axis in IBD. These results 
identify the mechanistic contributions of this IBD-linked pathway as a central 
regulator of ILC3 function in tissue homeostasis.   
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CHAPTER ONE: INTRODUCTION 
 
1.1 TL1A in Inflammatory Bowel Disease 
Inflammatory bowel disease (IBD) affects over 4 million people 
worldwide, causing significant morbidity among patients1. IBD 
pathogenesis is thought to be multifactorial, with both intestinal 
dysbiosis and genetic components underlying disease pathogenesis. 
Characteristic alterations in the IBD-associated microbiome exist, with 
marked contraction of intestinal microbial diversity a hallmark of IBD2.  
Genetic studies have identified over 200 genes linked with IBD3, but 
our functional understanding of how these genes contribute to 
intestinal homeostasis and IBD pathophysiology is incomplete, limiting 
the potential for diagnostic and therapeutic intervention.  
Genome-wide association studies (GWAS) in IBD have 
revealed the strongest associations of genetic variants in TNFSF15 
with Crohn’s disease, highlighting a central role for its protein, TNF-
like cytokine 1A (TL1A), in mucosal immunity4. TL1A, also known as 
vascular endothelial growth factor-251, is a member of the Tumor 
Necrosis Factor Superfamily (TNFSF) of ligands (TL1A is TNFSF15). 
In humans, TL1A consists of 251 amino acids and it shares 
approximately 30% homology with other TNF super family members, 
with the closest homology being TNF-a. On the cellular surface, TL1A 
is expressed of a membrane-bound protein (192 amino acids in the 
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extracellular domain, 24 in the transmembrane region and 35 amino 
acids in the cytoplastic tail), and is released as a soluble protein via 
cleavage by the metalloproteinase TNF-a converting enzyme, also 
known as TACE5,6.  
Genetically, variants in TNFSF15 have been linked to the 
pathogenesis of several autoimmune diseases—including psoriasis7–
10, rheumatoid arthritis11–19, and multiple sclerosis20–22—implicating a 
broader role for TL1A in human inflammatory diseases. In human 
patients, elevated TL1A is often detected at the site of inflammation, 
including the joints in rheumatoid arthritis (chondrocytes)11,23, in the 
intestinal tissue of IBD patients (mononuclear phagocytes)24 and in 
endothelial cells25,26. Over the past decade, numerous studies have 
illustrated a role for TL1A’s monogamous receptor, death receptor 3 
(DR3), in regulating lymphocyte cell function, with DR3 being 
predominantly expressed on lymphocyte populations and contributing 
to disease pathophysiology at mucosal barrier sites, including the 
intestine (Figure 1.1)4,24,27,28. In IBD, TNFSF15 variants confer higher 
risk for more aggressive, penetrating, fibrostenotic, and perianal 
disease complications29,30, but the mechanistic impact of TL1A 
remains controversial.  While early studies revealed a pathogenic role 
for TL1A in driving inflammatory T cell response28,31 more recent 
reports in acute colitis models revealing a protective role for TL1A32. 
Genetic models are needed to understand the cellular mechanisms 
and potential therapeutic targetability of this IBD-linked pathway in 
intestinal inflammation. 
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Figure 1.1. TL1A-DR3 axis regulates lymphocyte function. TL1A 
can be produced by a variety of cells, including MNP, endothelial cells 
and chondrocytes. TL1A binds to its receptor DR3 to regulate various 
lymphocytes functions, including ameliorating allergic asthma via T 
regs, promoting EAE pathophysiology via Th17, propagating allergic 
pneumonitis via ILC2-derived IL-13; however the role for DR3 in 
regulating ILC3 effector functions in the intestine has not been 
explored. Abbreviations: MNP (mononuclear phagocyte), TL1A (TNF-
like ligand 1A), DR3 (Death Receptor 3), T reg (T regulatory cell), 
Th17 (T-helper 17 cell) , EAE (experimental autoimmune 
encephalomyelitis) ILC2 (Group 2 Innate Lymphoid Cell), ILC3 (Group 
3 Innate Lymphoid Cell).  
 
ILC3 
Treg 
Th17 
Ameliorates allergic 
asthma 
Promotes EAE 
MNP 
Endothelial cell 
IL-13 in Allergic Pneumonitis 
Chondrocyte 
TL1A 
Mucosal barrier protection? 
Y 
DR3 
Y 
DR3 
Y 
DR3 
Y 
DR3 
ILC2 
4 
 
 
1.2 Mononuclear phagocytes and TL1A 
The innate immune response plays a central role in coordinating 
mucosal homeostasis24. As sentinels of barrier immunity, CX3CR1+ 
mononuclear phagocytes (MNPs) can extend transepithelial dendrites 
and integrate signals from the luminal microbiota33. These microbial 
signals act to reinforce intestinal compartmentalization by restricting 
migration of MNPs containing non-invasive luminal microbiota to 
secondary lymph organs34. Under inflammatory colitis, MNPs 
producing IL-23 and IL-1b expand within the lamina35–37and promote 
both T helper cell 17 (Th17)38 and Group 3 innate lymphocyte cell 
(ILC3)24 mucosal responses (Figure 1.2). MNP production of CXCL16 
promotes spatial co-localization with CXCR6+ NKp46+ ILC3s enabling 
rapid regulation of ILC3 effector cytokines to reinforce the barrier39,40. 
While recognition of stereotypical danger signals and spatial proximity 
within the lamina propria endows the innate immune system with the 
ability to swiftly respond to barrier injury, fine-tuning of this response is 
needed to confer selectivity and specificity. We recently showed that 
intestinal CX3CR1+ MNP produce TL1A whose gene, TNFSF15, 
encodes functional polymorphisms strongly associated with IBD24. 
Early studies showed that immune complex41 and microbial42 
stimulation of antigen presenting cells induced TL1A in vitro and acted 
as a co-stimulator of T helper cell 1 (Th1) inflammation28.  
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Figure 1.2. Functional roles for CX3CR1+ mononuclear 
phagocytes in intestinal barrier immunity.  CX3CR1+ MNP reside in 
the intestinal lamina propria and can extend transepithelial dendrites 
and integrate signals from the luminal microbiota to coordinate 
intestinal immune responses. These microbial signals act to reinforce 
intestinal compartmentalization by restricting migration of MNPs 
containing non-invasive luminal microbiota to secondary lymph 
organs. During colitis, MNPs expand within the lamina and modulate 
lymphocyte effector functions via the secretion of IL-23 and IL-1b. 
Abbreviations: MNP (mononuclear phagocyte), T reg (T regulatory 
cell), Th1 (T helper 1 cell), Th17 (T helper 17 cell) . 
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Subsequent studies revealed the ability to enhance Th17 effector 
function21,43 and promote T regulatory cell (T reg) ability to ameliorate 
allergic asthma44. 
More recent studies have illustrated a role for TL1A’s 
monogamous receptor DR3 in regulating innate lymphoid cell function. 
In a helminth infection model, DR3-deficient mice show increased 
susceptibility to infection secondary to a reduction in IL-13 production 
by ILC2s45. Additionally, parallel to the co-stimulator effect of TL1A on 
T cells, in vitro stimulation of ILC3 with TL1A synergizes with IL-23 to 
enhance effector cytokine production24. Although sustained 
overexpression of TL1A leads to chronic T cell-mediated colitis in 
mouse model27,31, recent studies in acute colitis models showing a 
protective role for DR332 highlight the need to understand the 
contribution of this pathway in innate immunity. 
 
1.3 Group 3 Innate Lymphoid Cells and TL1A 
Recent advances in sequencing technology have identified 
both microbial and host genetic factors with IBD and genome-wide 
association studies have identified over 160 genetic susceptibility 
loci3,46,47. Genetic polymorphisms at the IL23R locus correlate with 
susceptibility to both Crohn’s Disease (CD) and ulcerative colitis (UC), 
focusing attention on IL-23-responsive lymphocytes48–61.  An emerging 
group of innate lymphocyte that respond to IL-23 and express the 
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transcription factor RORgt have been characterized as group 3 innate 
lymphoid cells (ILC3).  
ILC3 are innate lymphocytes that play a critical role in 
regulating mucosal homeostasis. In response to environmental 
triggers, in particular the cytokines IL-23 and IL-1b, ILC3 produce 
robust amounts of IL-22 and play an important role in maintaining 
intestinal barrier integrity and promoting mucosal healing—a major 
clinical endpoint in IBD24.  Co-localization of ILC3 with CX3CR1+ 
MNPs in the lamina propria enables rapid regulation of ILC3 effector 
cytokines to reinforce barrier immunity and mucosal healing40. In 
response to IL-23, ILC3 produce robust amounts of IL-22, a cytokine 
that acts on epithelial cells to promote healing.   Recently, our lab 
identified that IBD patients with mild to moderate colitis have 
significantly higher IL-22 production by ILC3.  The production of IL-22 
in human IBD correlated with mucosal exposure to the fecal stream24.  
Similarly, studies using germ-free mice have established that ILC3 
effector cytokine function, including IL-22 production, is dependent on 
intestinal microbiota-derived signals40. At the steady-state, signaling 
by commensal organisms may negatively-regulate ILC3-derived IL-22 
via intestinal epithelial cell production of IL-2562; however, during 
experimental infectious colitis in mouse models and human IBD, 
intestinal microbial signals are not only required, but may actively 
enhance IL-22 production by ILC339. Intestinal MNPs expressing the 
fractalkine receptor CX3CR1+ interact with these intestinal microbes 
via their transepithelial dendrites and play a central role in integrating 
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the “crosstalk” between commensal microbes and effector 
lymphocytes, including ILC324,33,63. Furthermore, CX3CR1+ MNPs can 
migrate to secondary lymphoid organs and expand in the lamina 
propria during human and mouse colitis34.  These MNPs play a critical 
role in recruiting CXCR6+ ILC3 via CXCL16 production and regulating 
ILC3 production of both IL-22 and GM-CSF24,40.  While both MNP-
derived IL-23 and IL-1b are potent regulators of these ILC3 effector 
cytokines, the mechanisms underlying the cellular dialogue between 
CX3CR1+ MNP and ILC3, and in particular, the role for TL1A in 
regulating ILC3 function in intestinal homeostasis, and its potential 
contribution to IBD pathophysiology, remain unknown (Figure 1.3). 
Thus, the major aim of my thesis work has been to understand the 
potential role for CX3CR1+ MNP-derived TL1A signaling through DR3 
in coordinating ILC3-dependent barrier immunity. 
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Figure 1.3. Potential role for CX3CR1+ MNP-derived TL1A 
signaling through DR3 in coordinating ILC3-dependent barrier 
immunity. CX3CR1+ MNP integrate signals from the microbiota and 
promote mucosal healing by regulating ILC3 production of IL-22 via IL-
23 and IL-1b. Does CX3CR1+ MNP -derived TL1A promote intestinal 
barrier integrity and mucosal healing by regulating barrier immunity?  
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CHAPTER TWO: MONONUCLEAR PHAGOCYTE TL1A 
PROMOTES BARRIER PROTECTION DURING ACUTE 
INFLAMMATION 
 
2.1 ABSTRACT 
Inflammatory bowel disease (IBD) results from a dysregulated 
interaction between the microbiota and a genetically susceptible host.  
Genetic studies have linked TNFSF15 polymorphisms and its protein 
TNF-like ligand 1A (TL1A) with IBD, but the functional role of TL1A in 
linking tissue homeostasis and intestinal inflammation is not known. 
Here, using cell-specific genetic deletion models, we identified 
CX3CR1+ mononuclear phagocytes (MNP) as the main producer of 
intestinal TL1A in both mouse and humans, with IBD patients 
upregulating TL1A during active colitis. Furthermore, we report an 
essential role for CX3CR1+ MNP TL1A in promoting IL-22 dependent 
protection during acute colitis. Induction of TL1A by MNP was 
microbiota-dependent and potently induced by IBD-associated 
adherent-invasive microbes, conferring TL1A-dependent protection 
from acute colitis.   
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2.2  INTRODUCTION  
The innate immune response plays a central role in 
coordinating mucosal homeostasis24. As sentinels of barrier immunity, 
CX3CR1+ mononuclear phagocytes (MNPs) can extend transepithelial 
dendrites and integrate signals from the luminal microbiota33. These 
microbial signals act to reinforce intestinal compartmentalization by 
restricting migration of MNPs containing non-invasive luminal 
microbiota to secondary lymph organs34. Under inflammatory colitis, 
MNPs producing IL-23 and IL-1β expand within the lamina propria35–37 
and promote both Th1738 and ILC324 mucosal responses. MNP 
production of CXCL16 promotes spatial co-localization with CXCR6+ 
NKp46+ ILC3s enabling rapid regulation of ILC3 effector cytokines to 
reinforce the barrier40. While recognition of stereotypical danger 
signals and spatial proximity within the lamina propria endows the 
innate immune system with the ability to swiftly respond to barrier 
injury, fine-tuning of this response is needed to confer selectivity and 
specificity. We recently showed that intestinal CX3CR1+ MNP produce 
TL1A whose gene, TNFSF15, encodes functional polymorphisms 
strongly associated with IBD24. Early studies showed that immune 
complex41 and microbial42 stimulation of antigen presenting cells 
induced TL1A in vitro and acted as a co-stimulator of Th1 
inflammation28. Subsequent studies revealed the ability to enhance 
Th17 effector function21,43 and promote T reg ability to ameliorate 
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allergic asthma44. More recent studies have illustrated a role for 
TL1A’s monogamous receptor DR3 in regulating innate lymphoid cell 
function. In a helminth infection model, DR3-deficient mice show 
increased susceptibility to infection secondary to a reduction in IL-13 
production by ILC245. Additionally, parallel to the co-stimulator effect 
of TL1A on T cells, in vitro stimulation of ILC3 with TL1A synergizes 
with IL-23 to enhance effector cytokine production24. Although 
sustained overexpression of TL1A leads to chronic T cell-mediated 
colitis in mouse models27,31, recent studies in acute colitis models 
have demonstrated a protective role for DR332, highlighting the need 
to understand the role of this IBD-associated pathway in innate 
immunity. 
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2.3 METHODS 
Mice. C57BL/6, CD11c-cre, Cx3cr1GFP, and Cx3cr1CreER mice were 
purchased from The Jackson Laboratory. MyD88-/- were kindly provide 
by Julie Blander at Weill Cornell Medical College. CX3CR1-DTR mice 
were previously described34. TL1Aflox/flox mice were generated as 
follows: Tl1a endogenous locus containing 4.5 bp upstream and 3.4 
bp downstream of exon 1 were generated by PCR amplification using 
proprietary C57BL/6J library developed at genOway.  Subsequently, 
two loxP sites were inserted flanking Tl1a exon 1.  Positive selection 
neomycin gene flanked by FRT sites was inserted to the intron after 
exons 1 to generate the targeting vector. Every step of the cloning 
process was validated through restriction enzyme analysis and 
sequencing. The Tl1a gene targeting construct was linearized and 
electroporated into embryonic stem (ES) cells with C57BL/6J 
background.  Homologous recombinants were selected by G418 and 
confirmed by PCR and Southern blot analysis.  ES clones with correct 
5’ and 3’ recombination were microinjected into C57BL/6J blastocysts 
and introduced into pseudopregnant C57BL/6J mice.  Male chimeric 
offspring were bred to obtain germ line mutant mice, which were then 
bred to flpe delete mouse strain to remove the neomycin cassette and 
were confirmed by Southern blot.  For CX3CR1 depletion studies 
using Cx3cr1DTR mice, diptheria toxin was i.p. injected (200ng/200uL) 
for two consecutive days and then every 72 hours to maintain 
depletion. All experiments were performed with 6-8 week old 
littermates with random and equal assignment of same sex to each 
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experimental group.  All vertebrate work was approved by the IACUC 
at Weill Cornell Medicine. 
Human IBD subjects. A cohort of patients was evaluated for IBD at 
the Jill Roberts Center for IBD under Institutional Review Board–
approved protocol (1103011578) at Weill Cornell Medicine (WCM). 
Healthy control patients presented with abdominal pain but had 
normal endoscopic results; IBD patients were defined as having 
endoscopic inflammation with a history of ulcerative colitis or Crohn’s 
disease. All endoscopic biopsies were taken from the colon. 
Endoscopic biopsies from healthy control and IBD patients were 
transported in ice cold PBS and processed as previously reported24.  
 
Preparation of LPMC. Mouse intestines were washed in PBS and 1 
mM DTT with 30 mM EDTA, and then digested in collagenase 8 
(Sigma-Aldrich) and DNase-containing media with 10% fetal bovine 
serum. Digested material was passed through a cell strainer and 
separated by a 40% Percoll gradient. For intracellular cytokine 
staining, LPMCs were cultured ex vivo in the presence of GolgiPlug 
(BD) for 4 h or stimulated with phorbol myristate acetate (PMA; 20 
ng/ml) and ionomycin (1 μg/ml) or IL-23 (40 ng/ml; eBioscience) in the 
presence of GolgiPlug (BD) for 4 h before staining. All TL1A detection 
was done by extracellular flow cytometry staining. 
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Antibodies and flow cytometry.  Staining of cells was performed 
with the following antibodies: 
Table 2.1 Flow cytometry antibodies used in chapter 2. 
Species Target Fluorophore Clone Manufacturer 
Mouse CD3 FITC 145-2C11 eBioscience 
Mouse CD4 eFluor780 RM4-5 eBioscience 
Mouse CD5 PE 53-7.3 eBioscience 
Mouse MHCII Alexa700  M5/114.15.2 eBioscience 
Mouse F4/80 PE BM8 eBioscience 
Mouse CD19 FITC MB19-1 eBioscience 
Mouse CD11b eFluor780  M1/70 eBioscience 
Mouse CD11c PE-Cy7 N418 eBioscience 
Mouse CD103 APC 2E7 eBioscience 
Mouse TCRgd FITC 11-5711-82 eBioscience 
Mouse KLRG1 PE 2F1 eBioscience 
Mouse CD127 PE-Cy7  A7R34 BioLegend 
Mouse CCR6 BV421 29-2L17 BioLegend 
Mouse DR3 PE 4C12 BioLegend 
Mouse RORgt PE B2D eBioscience 
Mouse T-bet e660 eBio4B10 eBioscience 
Mouse Foxp3 e450 FJK-16s eBioscience 
Mouse IL-22 APC IL22JOP eBioscience 
Mouse IL-17 PE eBio17B7 eBioscience 
Mouse IFNg PE-Cy7  XMG1.2 eBioscience 
Mouse TL1A e710 Tandys1a eBioscience 
Human CD14 PE 61D3 eBioscience 
Human CD14 Alexa700 63D3 eBioscience 
Human HLA-DR Alexa700 LN3 eBioscience 
Human TL1A e710 Tandys1a eBioscience 
Human CD45 APC 2D1 eBioscience 
Human CD3 eFluor780 UCHT1 eBioscience 
Human CD19 Alexa700 HIB19 eBioscience 
Human CD127 PE-Cy7 eBioRDR5 eBioscience 
Human CD117 efluor450 104D2 eBioscience 
Human CD5 eFluor780 UCHT1 BioLegend 
Human CD11c Alexa700 3.9 Invitrogen 
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 Dead cells were excluded using the Live/Dead fixable aqua dead cell 
stain kit (Invitrogen). Intracellular cytokine staining was performed 
according to the manufacturer’s protocol (Cytofix/Cytoperm buffer set; 
BD) and transcription factor staining for was performed according to 
manufacturer’s protocol (Intracellular Fixation and Permeabilization kit; 
eBioscience). Flow cytometry was performed with a BD LSRFortessa 
and analyzed with FlowJo software (Tree Star).  
 
Colitis models. To induce chemical colitis in mice, 2% DSS (w/v) 
(M.W. 40,000-50,000; Affymetrix) was added to sterile drinking water 
and administered ad libitum for 7 days. After 7 days, DSS was 
replaced with normal drinking water. To induce infectious colitis, mice 
were orally gavaged with log phase growth Citrobacter rodentium 
DBS100 (ATCC 51459; American Type Culture Collection) at 1x1010 in 
PBS. For all colitis experiments, mice were monitored daily (DSS) or 
weekly (T-cell transfer) for weight loss, rectal bleeding, diarrhea and 
survival throughout the experiments. For in vivo experiments using 
AIEC 2A, mice were pre-treated for 21 days with a broad-spectrum 
antibiotic cocktail of ampicillin (1g/L), neomycin (0.5g/L), 
metronidazole (0.5g/L) and vancomycin (0.5g/L) in their drinking 
water. Mice were then orally gavaged with 2x109 of AIEC 2A before 
colitis induction with 2% DSS in their drinking water. 
qPCR. RNA from primary intestinal cell populations was prepared with 
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TRIzol (Invitrogen) and purified RNA was reverse transcribed into 
cDNA (Quanta qScript). qPCR was performed with a QuantStudio 6 
Flex  Real-time PCR (Applied Biosystems) with SYBR Green 
Supermix (Bio-Rad Laboratories). The following primers were used: 
Tnfsf15: 5’-ATGCTTCGGGCCATAACAGA-3’ and 5’-
TGAAGGCCATCCCTAGGTCA-3’. Hprt: 5’-
GAGGAGTCCTGTTGATGTTGCCAG-3’  5’-
GGCTGGCCTATAGGCTCATAGTGC-3’.  
The thermocycler program was as follows: initial cycle of 95oC for 60s, 
followed 40 PCR cycles at 95oC for 5s, 60oC for 15s, 72oC for 15s. 
Relative levels of the target genes were determined by using the ΔΔCt 
of the target gene compared to Hprt expression. 
Statistical analysis. Statistical analysis was performed in GraphPad 
Prism or R software. Results represent mean ± s.e.m. and were 
analyzed by unpaired Student’s t-test, Mann-Whitney test, one-way 
ANOVA, Log-rank (Mantel-Cox) test, as indicated in the figure 
legends. Given that mouse experiments required littermate controls 
and complex genotyping, experimental group allocation was not 
blinded. No relevant exclusion criteria were applied.  
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2.4 RESULTS 
2.4.1 Intestinal MNPs express high levels of TL1A  
Previous reports have identified MNPs as a source of intestinal 
TL1A in mouse and humans64.  TL1A can be expressed by many cell 
types, but the highest transcriptional levels of TNFSF15 is seen in 
antigen presenting cells.  Mouse studies from our lab have previously 
published that CX3CR1+ MNPs express higher TNFSF15 than gut 
derived B cells, CD103+ conventional dendritic cells, or Ly6C+ 
monocytes24.  To evaluate TL1A expression by human intestinal 
lymphocyte populations, we performed flow cytometry on lamina 
propria mononuclear cells from endoscopic biopsies from healthy 
patients undergoing routine coloscopy screening. Our flow cytometric 
analysis of human intestinal biopsies identified  CD14+/HLA-DRhi 
intestinal MNPs during colitis as having significantly higher expression 
of TL1A compared to CD3+CD4+ T cells or CD19+ B cells, consistent 
with our previous mouse studies identifying MNP as a dominant 
source of TL1A in the intestine (Figure 2.1)24.  
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Figure. 2.1. Human MNP express TL1A. (A, B) T cells (CD3+CD4+), 
B cells (CD19+) and MNPs (CD14+ HLA-DR+) were identified from 
human intestinal biopsies by flow cytometry (A) and TL1A surface 
expression is shown (B), (n = 4). Data in (B) are mean ± s.e.m and 
were analyzed by two-tailed Student’s t-test; ***P<0.001.   
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2.4.2  Human MNP upregulate TL1A during colitis 
CX3CR1+ MNPs play a central role in coordinating the ILC3-
dependent mucosal response during colitis24,39.  Recent studies have 
reported increased TL1A levels in the colonic tissue of both mouse 
and humans during active colitis64. To evaluate the contribution of 
TL1A expression by CD14+/HLA-DRhi intestinal MNPs, we performed 
flow cytometry on lamina propria mononuclear cells from endoscopic 
biopsies from healthy (N=7) and IBD patients (N=8) (Figure 2.2A).  
MNPs from IBD patients with active inflammation showed significantly 
higher surface expression of TL1A (Figure 2.2B).   
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Figure. 2.2. Human MNP upregulate TL1A during colitis. (A, B) 
CD14+ HLA-DR+ MNPs were identified from human intestinal biopsies 
(IBD=8, Healthy=7) by flow cytometry and TL1A surface expression is 
shown. Data in (B) are mean ± s.e.m and were analyzed by two-tailed 
Student’s t-test; ***P<0.001.   
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2.4.3  CX3CR1+ MNPs are the dominant source of intestinal TL1A  
 Consistent with these data from human IBD, selective depletion 
of CX3CR1+ MNP using mice harboring a diphtheria toxin receptor 
insertion into the Cx3cr1 locus (CX3CR1DTR) following diphtheria toxin 
injection significantly reduced TL1A expression in the intestinal lamina 
propria (Figure 2.3).   
            
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure. 2.3. CX3CR1+ MNP are the dominant source of intestinal 
TL1A. (A ) TL1A expression by qPCR from intestinal lamina propria 
mononuclear cells from CX3CR1DTR mice or controls after DT toxin 
injection (n = 4 mice/group). Data in (B) are mean ± s.e.m and were 
analyzed by two-tailed Student’s t-test. ***P<0.001.    
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2.4.4  MNP-specific deletion of TL1A impairs wound healing  
 To evaluate the potential physiological role for MNP-derived 
TL1A in colitis, we generated a novel TL1A conditional knockout allele 
with loxP-flanked Tnfsf15 (TL1Aflox/flox) and then crossed these mice to 
transgenic mice expressing the Cre recombinase under the CD11c 
promoter (TL1AΔCD11c) (Figure 2.4A).  TL1A mRNA expression in 
lamina propria CD11c+ cells was used to confirm deletion (Figure 
2.4B). TL1AΔCD11c mice exposed ad libitum to 2% dextran sodium 
sulfate (DSS) for seven days lost significantly more weight than their 
littermate controls (Figure 2.4C,D).    
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Figure 2.4. MNP-specific deletion of TL1A impairs mucosal 
wound healing during acute colitis. (A) Generation of MNP-specific 
TL1A genetic deletion model. (B ) TL1A mRNA expression in FACS-
sorted MHCII+CD11c+ MNPs from TL1Aflox/flox or TL1AΔCD11c littermate 
mice was determined by qPCR (n = 3, 4 mice group, respectively).  
(C) Experimental design for TL1Aflox/flox or TL1AΔCD11c littermate mice 
treated with 2% DSS for 7 days. (D) Weight loss curves of 2% DSS-
treated TL1Aflox/flox or TL1AΔCD11c littermate mice (n = 10, 9 mice/group, 
respectively, pooled from two independent experiments). Data in (B) 
are mean ± s.e.m and were analyzed by two-tailed Student’s t-test. 
Data in (D) are mean ± s.e.m and were analyzed by two-tailed Mann-
Whitney test; *P<0.05, ***P<0.001.   
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2.4.5  CX3CR1+ MNP-specific TL1A deletion impairs barrier 
protection  
To specifically test the role for CX3CR1+ MNP-derived TL1A, we 
crossed TL1Aflox/flox mice with transgenic mice expressing a tamoxifen-
inducible Cre recombinase under control of the Cxc3cr1 promoter 
(TL1AΔCX3CR1) (Figure 2.5A).  Transcriptional analysis validated that 
TL1AΔCX3CR1 mice selectively lacked TL1A expression on 
CD11C+MHCII+CD11b+ MNPs following induction with tamoxifen 
(Figure 2.5B). To examine a role for CX3CR1+ MNP-derived TL1A in 
vivo, TL1AΔCX3CR1 and their littermate TL1Aflox/flox controls were 
exposed to 2% DSS for seven days (Figure 2.5C).  TL1AΔCX3CR1 mice 
lost significantly more weight than their littermate controls, had 
increased histopathological damage, and reduced IL-22 production in 
ILC3 (Figure 2.5C-E); however, IL-17 and IFN-g production by ILC3 or 
T cells was not impaired (Figure 2.6A-C).  To test the role for 
CX3CR1+ MNP-derived TL1A in a secondary colitis model, we 
colonized TL1AΔCX3CR1 and their littermate TL1Aflox/flox controls with 
Citrobacter rodentium. Similar to the DSS colitis experiments, 
TL1AΔCX3CR1 mice lost significantly more weight than their littermate 
controls (Figure 2.7). 
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Figure 2.5. CX3CR1+ MNP-specific deletion of TL1A impairs barrier 
protection during acute colitis. (A) Generation of CX3CR1+ MNP-specific 
TL1A genetic deletion model. (B) qPCR of TL1A expression in 
MHCII+CD11c+CD11b+CX3CR1YFP MNPs from 4OHT-treated TL1AΔCX3CR1 
and TL1Aflox/flox littermate mice. (C) Weight loss curves of 2% DSS-treated 
TL1Aflox/flox or TL1AΔCX3CR1 littermate mice (n = 10, 7 mice/group, respectively, 
pooled over two experiments). (D) Representative colonic histology from 
TL1AΔCX3CR1 or TL1Aflox/flox mice littermate mice following 2% DSS treatment 
for 9 days. (E) Flow cytometric analysis of IL-22 production by ILC3 from 
TL1Aflox/flox or TL1AΔCX3CR1 mice on day 3 after starting 2% DSS treatment (n 
= 10, 5 mice/group, respectively). Data in (B) and (E) are mean ± s.e.m and 
were analyzed by two-tailed Student’s t-test. Data in (C) are mean ± s.e.m 
and were analyzed by two-tailed Mann-Whitney test; *P<0.05, **P<0.01, 
***P<0.001.   
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Figure 2.6. MNP-specific deletion of TL1A does not impair ILC3 or 
T cell IFN-g or IL-17 production. (A) Flow cytometric analysis of IL-
17 and IFN-ɣ expression in Lin-CD127+RORɣt+ ILC3 from TL1AΔCD11c 
or TL1Aflox/flox control mice after 2% DSS treatment for three days (n = 
4-5 mice/group); data are represented as mean ± s.e.m and were 
analyzed by two-tailed Student’s t-test; ns = not statistically significant; 
nd= not detected. (B, C) Quantification of CD3+CD4+ T cell 
transcription factors (B) and cytokine expression (C) from from 
TL1AΔCD11c or TL1Aflox/flox control mice after 2% DSS treatment for 
three days (n = 5 mice/group); data are represented as mean ± s.e.m 
and were analyzed by two-tailed Student’s t-test; ns = not statistically 
significant; nd= not detected.  
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Figure 2.7 CX3CR1+ MNP-specific deletion of TL1A impairs barrier 
protection during infectious colitis. (A) Weight loss curves of 
TL1Aflox/flox or TL1AΔCX3CR1 littermate mice infected with Citrobacter 
rodentium (n = 6 mice/group, pooled over two experiments). Data are 
mean ± s.e.m and were analyzed by two-tailed Mann-Whitney test; 
**P<0.01. 
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2.4.6  MNP TL1A Induction is microbiota-dependent  
CX3CR1+ MNP are uniquely positioned at the intestinal barrier 
to sample luminal microbes33. Given the ability of bacterial signals to 
induce TL1A mRNA in human antigen-presenting cells42, we 
evaluated the role for microbial regulation of TL1A in vivo using germ-
free and antibiotic-treated mice compared to specific pathogen free 
(SPF) control mice.  Flow cytometric analysis of TL1A expression in 
CD11c+ MHCII+ CD11b+ MNPs showed that germ-free mice and 
antibiotic-treated mice had a significant reduction in intestinal TL1A 
compared to SPF mice (Figure 2.8).   
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Figure 2.8. Intestinal microbes induce TL1A in MNP. (A) Flow 
cytometric analysis of TL1A expression in MHCII+CD11c+CD11b+ 
MNP from germ-free (GF) or specific-pathogen-free (SPF) mice. (B) 
Flow cytometric analysis of TL1A expression in 
MHCII+CD11c+CD11b+GFP+ MNP from antibiotic-treated (ABX) or 
untreated specific-pathogen-free (SPF) CX3CR1GFP/WT mice.  
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2.4.7  IBD-associated adherent microbes induce TL1A  
Previous studies have reported that microbial adherence to the 
intestinal epithelial surface may play a critical role in regulating 
immune responses in the lamina propria.  Segmented filamentous 
bacteria (SFB), for example, adheres tightly to the ileal mucosa and 
induces Th17 and ILC3 effector function65,66.  Given the importance of 
CX3CR1+ MNP in regulating this interaction24,38, we sought to examine 
the role for SFB in TL1A regulation.  Lamina propria MNPs from germ-
free and gnotobiotic mice colonized with SFB were analyzed for TL1A 
expression (Figure 2.9A).  SFB mono-colonized mice had significantly 
higher levels of intestinal TL1A compared to GF mice. To further test if 
this induction of TL1A was selective for adherent bacteria, we used 
Adherent-invasive E. coli (AIEC) strain 2A and a non-adherent E. coli 
control strain T75 derived from patients with Crohn’s disease67.  At 5 
days following colonization, AIEC strain 2A, but not T75, induced 
TL1A in the colonic lamina propria (Figure 2.9B).  
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Figure 2.9. IBD-associated adherent microbiota induce TL1A in 
intestinal MNP. (A) Experimental design for colonization of germ-free 
mice with human IBD-associated microbes. (B)  Germ-free mice were 
mono-colonized with media control, SFB, non-adherent E. coli T75, 
Adherent-invasive E. coli 2A for 5 days.  MNPs were sorted from the 
lamina propria and Tnfsf15 expression determined by quantitative 
PCR. Data in (B) are mean ± s.e.m and were analyzed by two-tailed 
Student’s t-test; *P<0.05, **P<0.01. 
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2.4.8  IBD-associated adherent microbes promote barrier 
protection  
We recently showed that AIEC are protective during acute 
colitis67, so we next asked if the protective effects of AIEC are 
dependent on MNP-derived TL1A.  To test the role of microbe-induced 
MNP TL1A in acute colitis, TL1AΔCD11c and littermate TL1Aflox/flox mice 
were pre-treated with broad-spectrum antibiotics and then colonized 
with AIEC strain 2A prior to DSS exposure (Figure 2.10A).  
Colonization with AIEC was sufficient to rescue the more severe 
weight loss and reduced survival following treatment with antibiotics, 
and this rescue required MNP-derived TL1A (Figure 2.10B,C).  
Collectively, these findings reveal a critical beneficial role for IBD-
associated adherent microbiota induction of MNP-derived TL1A to 
promote protection from acute colitis. 
 
 
 
 
  
34 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.10. IBD-associated adherent microbiota protect from 
acute colitis via MNP-derived TL1A. (A) Experimental design for 
testing gene-microbe interactions during colitis. TL1Aflox/flox and 
TL1AΔCD11c were treated with broad-spectrum antibiotics for three 
weeks before colonization with 2A E. coli. Mice were then mice treated 
with 2% DSS for 7 days. (B, C) Percent survival (B) and weight loss 
(C) is shown. Data in (B) are mean ± s.e.m and were analyzed by two-
tailed Student’s t-test. Data in (B) are mean ± s.e.m and were 
analyzed by Log-rank (Mantel-Cox) test  or by one-way ANOVA with 
multiple comparisons test (C); *P<0.05, **P<0.01. 
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2.5  DISCUSSION 
As sentinels of barrier immunity, MNPs integrate microbial 
signals and activate both innate and adaptive effector immunity.  By 
producing IL-23 and IL-1b, as well as CXCL16, MNPs are well-
positioned functionally and spatially to rapidly coordinate ILC3 effector 
cytokine production including IL-2224,39. However, if and how other 
MNP-derived genes regulate ILC3 functions in the intestine are 
currently unknown. In this chapter, we report that the IBD-associated 
gene TNFSF15, which encodes for the functional protein TL1A, is 
critical for ILC3-mediated intestinal barrier protection.  
Here, we identify the CX3CR1+ MNP as the dominant producers 
of intestinal TL1A in both mouse and human IBD patients. Using cell-
specific genetic knockout models, mice with TL1A deletion in MNPs 
and CX3CR1+ MNP, specifically, were significantly more susceptible to 
chemically-induced and infectious colitis damage than their littermate 
controls. Furthermore, MNPs from the mucosal biopsies of human IBD 
patients with active colitis produced robust amounts of TL1A 
compared to non-IBD patients, suggesting a potential role for MNP-
derived TL1A during active colitis in IBD patients. However, how 
specific TNFSF15  mutations (either loss-of-function or gain-of-
function mutations) contribute to disease outcomes in IBD patients 
remains to be explored and could offer a potential avenue for 
therapeutic intervention. 
Our results support a key role for microbial regulation of MNP-
derived TL1A. Germ-free mice, or mice treated with board-spectrum 
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antibiotics, had remarkably decreased levels of TL1A compared to 
conventionally housed mice, suggesting that intestinal microbes are 
key regulators of lamina propria TL1A. Specifically, adherent, IBD-
associated adherent microbes, including segmented filamentous 
bacteria (SFB) and Adherent-invasive E. coli enriched in Crohn’s 
disease, robustly induced TL1A, consistent with their ability to potently 
induce ILC3 production of IL-2266,67. Furthermore, in vivo models 
using cell-specific deletion of TL1A in MNPs demonstrated that these 
adherent microbes were unable to rescue antibiotic-treated mice from 
DSS colitis, suggesting a gene-microbe link between adherent 
microbes and MNP-derived TL1A in mediating barrier protection. 
However, it remains to be seen whether this protective effect is via 
ILC3 IL-22 or by other mechanisms. 
These findings offer a mechanism by which Crohn’s disease-
associated microbiota can act acutely to promote barrier immunity in 
wild-type hosts.  The adherence and metabolic characteristics of the 
intestinal microbiota may offer a novel approach for regulating TL1A 
effects in the mucosa.   
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CHAPTER THREE: ILC3-SPECIFIC DR3 PROMOTES BARRIER 
PROTECTION DURING ACUTE COLITIS 
3.1  ABSTRACT 
In chapter two, we demonstrated an essential role for CX3CR1+ MNP-
derived TL1A in mucosal barrier immunity. Deletion of CX3CR1+ MNP-
intrinsic TL1A exacerbated intestinal inflammation by restraining ILC3 
cytokine production and mucosal healing. In the intestine, CX3CR1+ 
MNP-derived TL1A was dependent on luminal microbes and potently 
induced by attaching/invasive bacteria. To examine the physiologic 
role for the TL1A:DR3 axis in mucosal healing, we generated novel 
genetic mouse models with targeted DR3 deletion on ILC3 (DR3ΔILC3). 
Whole body DR3-/- and ILC3-specific DR3ΔILC3 mice exposed to 
experimental colitis had more severe weight loss, pathology, and 
reduced survival; this phenotype correlated with reduced ILC3 
production of IL-22, epithelial cell anti-microbial peptide production 
and was rescued by recombinant IL-22. Mechanistically, inhibition of 
p38-MAPK disrupted TL1A signaling on ILC3 by impairing effector 
cytokine. In vivo, mice with mice with a double deletion of DR3 and 
IL23R (DR3-/- IL23R-/-) had decreased survival compared to mice with 
single deletions in either DR3 or IL23R, highlighting a synergistic role 
for DR3/IL23R signaling in promoting mucosal healing in vivo. 
Collectively, these data highlight a key role for ILC3-specific DR3 
signaling in regulating intestinal barrier immunity in vivo. 
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3.2 INTRODUCTION 
Genome-wide association studies (GWAS) in IBD have 
revealed the strongest associations of genetic variants in TNFSF15 
with Crohn’s disease, highlighting a central role for its protein, TNF-
like cytokine 1A (TL1A), in mucosal immunity46. Variants in TNFSF15 
have been linked to the pathogenesis of several autoimmune 
diseases—including psoriasis, rheumatoid arthritis, and multiple 
sclerosis—implicating a broader role for TL1A in human inflammatory 
diseases4.  In IBD, TNFSF15 variants confer higher risk for more 
aggressive, penetrating, fibrostenotic, and perianal disease 
complications29,30, but the mechanistic impact of TL1A remains 
controversial.  While early studies revealed a pathogenic role for TL1A 
in driving inflammatory T cell response28,31, more recent reports in 
acute colitis models revealing a protective role for TL1A32. Genetic 
models are needed to understand the cellular mechanisms and 
potential therapeutic targetability of this IBD-linked pathway in 
intestinal inflammation. 
Group 3 innate lymphoid cells (ILC3) are an emerging class of 
innate lymphocytes that play a critical role in regulating mucosal 
homeostasis68–74. In response to environmental triggers, in particular 
the cytokines IL-23 and IL-1b, ILC3 produce robust amounts of IL-22 
and play an important role in maintaining intestinal barrier integrity and 
promoting mucosal healing—a major clinical endpoint in IBD24,74,75. 
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Co-localization of ILC3 with CX3CR1+ mononuclear phagocytes 
(MNPs) in the lamina propria enables rapid regulation of ILC3 effector 
cytokines to reinforce barrier immunity and mucosal healing39. Both 
mouse and human ILC3s express Death Receptor 3 (DR3), the 
monogamous receptor for TL1A, on its surface, with TL1A stimulation 
promoting ILC3 proliferation76 and cytokine production in vitro24; 
however, the role for TL1A in regulating ILC3 function in intestinal 
homeostasis, and its potential contribution to IBD pathophysiology, 
remains unknown.   
Here, we generated mouse models with selective deletion of 
DR3 on ILC3 to evaluate the contribution of this critical IBD-linked 
genetic pathway in regulating mucosal immunity.  Our data reveal a 
critical role for ILC3-specific DR3 acting synergistically with IL23R 
signaling in promoting mucosal healing in acute colitis. In vitro, DR3 
signaling on ILC3 was dependent on TAK1 and p38-MAPK signaling. 
In vivo, mice with mice with a double deletion of DR3 and IL23R  
(DR3-/- IL23R-/-) had decreased survival compared to mice with single 
deletions in either DR3 or IL23R, highlighting a synergistic role for 
DR3/IL23R signaling in promoting mucosal healing in vivo. These 
results highlight the central role for IBD-linked TL1A in regulating ILC3 
barrier immunity. 
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3.3  METHODS 
Mice. C57BL/6 mice were purchased from The Jackson Laboratory. .  
Il23rGFP mice were obtained from M. Oukka77.  DR3-/- mice were 
obtained from Cancer Research UK (E. Wang). Generation of 
Dr3flox/flox mice is previously described78. All experiments were 
performed with 6-8 week old littermates with random and equal 
assignment of same sex to each experimental group.  All vertebrate 
work was approved by the IACUC at Weill Cornell Medicine. 
 
Preparation of LPMC. Mouse intestines were washed in PBS and 1 
mM DTT with 30 mM EDTA, and then digested in collagenase 8 
(Sigma-Aldrich) and DNase-containing media with 10% fetal bovine 
serum. Digested material was passed through a cell strainer and 
separated by a 40% Percoll gradient. For intracellular cytokine 
staining, LPMCs were cultured ex vivo in the presence of GolgiPlug 
(BD) for 4 h or stimulated with phorbol myristate acetate (PMA; 20 
ng/ml) and ionomycin (1 μg/ml) or IL-23 (40 ng/ml; eBioscience) in the 
presence of GolgiPlug (BD) for 4 h before staining. All TL1A detection 
was done by extracellular flow cytometry staining. 
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Antibodies and flow cytometry. Staining of cells was performed with 
the following antibodies: 
Table 3.1. Flow cytometry antibodies used in chapter 3. 
Species Target Fluorophore Clone Manufacturer 
Mouse CD3 FITC 145-2C11 eBioscience 
Mouse CD4 eFluor780 RM4-5 eBioscience 
Mouse CD5 PE 53-7.3 eBioscience 
Mouse CD45.1 APC A20 eBioscience 
Mouse CD90.2 efluor450  53-2.1 eBioscience 
Mouse MHCII Alexa700  M5/114.15.2 eBioscience 
Mouse F4/80 PE BM8 eBioscience 
Mouse Ly6C eFluor450  HK1.4 eBioscience 
Mouse CD19 FITC MB19-1 eBioscience 
Mouse CD11b eFluor780  M1/70 eBioscience 
Mouse CD11c PE-Cy7 N418 eBioscience 
Mouse CD103 APC 2E7 eBioscience 
Mouse TCRgd FITC 11-5711-82 eBioscience 
Mouse KLRG1 PE 2F1 eBioscience 
Mouse NKp46 eFluor710  29A1.4 eBioscience 
Mouse OX40L APC RM134L eBioscience 
Mouse ICOSL  eFluor660 HK5.3 eBioscience 
Mouse CD127 PE-Cy7  A7R34 BioLegend 
Mouse CCR6 BV421 29-2L17 BioLegend 
Mouse DR3 PE 4C12 BioLegend 
Mouse RORgt PE B2D eBioscience 
Mouse T-bet e660 eBio4B10 eBioscience 
Mouse Foxp3 e450 FJK-16s eBioscience 
Mouse IL-22 APC IL22JOP eBioscience 
Mouse GMCSF FITC MP1-22E9 eBioscience 
Mouse IL-13 PE-Cy7 eBio13A eBioscience 
Mouse IL-17 PE eBio17B7 eBioscience 
Mouse IFNg PE-Cy7  XMG1.2 eBioscience 
Mouse TL1A e710 Tandys1a eBioscience 
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Dead cells were excluded using the Live/Dead fixable aqua dead cell 
stain kit (Invitrogen). Intracellular cytokine staining was performed 
according to the manufacturer’s protocol (Cytofix/Cytoperm buffer set; 
BD) and transcription factor staining for was performed according to 
manufacturer’s protocol (Intracellular Fixation and Permeabilization kit; 
eBioscience). Flow cytometry was performed with a BD LSRFortessa 
and analyzed with FlowJo software (Tree Star).  
 
Colitis models. To induce chemical colitis in mice, 2% DSS (w/v) 
(M.W. 40,000-50,000; Affymetrix) was added to sterile drinking water 
and administered ad libitum for 7 days. After 7 days, DSS was 
replaced with normal drinking water. To induce infectious colitis, mice 
were orally gavaged with log phase growth Citrobacter rodentium 
DBS100 (ATCC 51459; American Type Culture Collection) at 1x1010 in 
PBS. For all colitis experiments, mice were monitored daily weight 
loss, rectal bleeding, diarrhea and survival throughout the 
experiments.  
qPCR. RNA from primary intestinal cell populations was prepared with 
TRIzol (Invitrogen) and purified RNA was reverse transcribed into 
cDNA (Quanta qScript). qPCR was performed with a QuantStudio 6 
Flex  Real-time PCR (Applied Biosystems) with SYBR Green 
Supermix (Bio-Rad Laboratories). The following primers were used:  
Il22: 5’-GCTCAGCTCCTGTCACATCA-3’ and 5’-
CAGTCCCCCAATCGCCTTGA-3’ 
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Hprt: 5’-GAGGAGTCCTGTTGATGTTGCCAG-3’  5’-
GGCTGGCCTATAGGCTCATAGTGC-3’.  
The thermocycler program was as follows: initial cycle of 95oC for 60s, 
followed 40 PCR cycles at 95oC for 5s, 60oC for 15s, 72oC for 15s. 
Relative levels of the target genes were determined by using the ΔΔCt 
of the target gene compared to Hprt expression. 
Statistical analysis. Statistical analysis was performed in GraphPad 
Prism or R software. Results represent mean ± s.e.m. and were 
analyzed by unpaired Student’s t-test, Mann-Whitney test, one-way 
ANOVA, Log-rank (Mantel-Cox) test, as indicated in the figure 
legends. Given that mouse experiments required littermate controls 
and complex genotyping, experimental group allocation was not 
blinded. No relevant exclusion criteria were applied.  
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3.4  RESULTS 
3.4.1  DR3 signaling protects from intestinal injury 
 To evaluate the impact of endogenous TL1A in vivo using 
experimental colitis models, mice deficient for DR3 were exposed ad 
libitum to 2% DSS.  Similar to recent results32, DSS induced more 
severe acute colitis in mice deficient for DR3, as evidenced by 
increased weight loss with a protracted recovery (Figure 3.1A), 
reduced survival (Figure 3.1B) and increased histopathological 
damage (Figure 3.2C).  Analysis of CD4+ T cell population in the 
lamina propria did not reveal significant differences in Foxp3+ 
regulatory CD4+ T cells, IL-17 producing RORgt+ Th17 cells (Figure 
3.2A-C), or IL-13 producing ILC2 cells (data not shown). In contrast, 
Lin- RORgt+ ILC3 from the lamina propria showed a significant 
decrease in IL-22 (Figure 3.4A); there were no changes in the total 
numbers of ILC3 or in ILC3 subsets (Figure 3.3). To evaluate the 
contribution of reduced ILC3 production of IL-22 to this phenotype, we 
injected DR3-deficient mice with recombinant IL-22 following exposure 
to DSS; treatment with rIL-22 completely rescued DR3-deficient mice, 
suggesting a critical role for ILC3-derived IL-22 in mediating this colitis 
phenotype (Figure 3.4B).  
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Figure 3.1. DR3 protects mice from experimental colitis.  (A,B) 
Body weights (A) and survival curves (B,D) of DR3+/- and DR3-/- 
littermate mice following 7 day treatment with 2% DSS. Data are 
compiled from three independent experiments (with n = 34, 25 
mice/group for DR3+/- and DR3-/-, respectively); (C) Representative 
colonic histology and colonic scoring from DR3+/- and DR3-/- littermate 
mice following 2% DSS treatment for 7 days (analyzed in A, B). Data 
in (A) are mean ± s.e.m. and analyzed by Mann-Whitney test; data in 
(B) were analyzed by Log-rank (Mantel-Cox) test; *P<0.05, 
***P<0.001.  
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Figure 3.2. DR3 deletion does not alter T cell function during 
acute colitis. (A, B) Flow cytometric analysis (A) and quantification 
(B) of T cell transcription factors and cytokine production in CD3+CD4+ 
T cells from DR3+/- or DR3-/- control mice after 2% DSS treatment for 
three days (n = 8 mice/group compiled over two experiments); data 
are represented as mean ± s.e.m and were analyzed by two-tailed 
Student’s t-test; ns = not statistically significant. 
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Figure 3.3. DR3 deletion does not alter ILC3 subsets during acute 
colitis.  (A, B) Flow cytometric analysis (A) and quantification (B) of 
Lin-CD127+RORɣt+ ILC3 subsets from DR3+/-RAG2-/- or DR3-/-RAG2-/- 
control mice after 2% DSS treatment for seven days (n = 3-4 
mice/group); data are represented as mean ± s.e.m and were 
analyzed by two-tailed Student’s t-test; ns = not statistically significant. 
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Figure 3.4. ILC3 expression of DR3 plays an essential role in 
regulating IL-22-dependent protection from experimental colitis.  
(A) Percentage of colonic Lin-CD127+CD90+RORγt+ ILC3s producing 
IL-22 from DSS-treated DR3+/- and DR3-/- co-housed littermate mice 9 
days after starting DSS treatment (n = 4-5 mice/group). (B) Survival 
curves of DR3+/-, DR3-/-, and  DR3-/- + rIL-22, mice following 7 day 
treatment with 2% DSS. Data are compiled from three independent 
experiments (with n = 34, 25, 4 mice/group for DR3+/-, DR3-/-, and  
DR3-/- + rIL-22, respectively); i.v. rIL-22 was given on days 4 and 6 
following initiation DSS. Data (A) are mean ± s.e.m and analyzed by 
two-tailed Student’s t-test; ***P<0.001.  
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3.4.2  Generation of ILC3-specific DR3 deletion genetic model 
To specifically test the importance of ILC3-intrinsic DR3 
signaling in intestinal barrier immunity, we crossed mice with a loxP-
flanked Tnfrsf25 (DR3flox/flox) to transgenic mice expressing the Cre 
recombinase from the RORgt promoter (Rorccre) on a RAG2-deficient 
background (called DR3ΔILC3).  Transcriptional and flow cytometric 
analysis revealed that DR3ΔILC3 mice lacked DR3 expression on ILC3, 
but not on ILC2, confirming cell type-specific DR3 deletion (Figure 
3.5).  Absence of DR3 did not change the total number or frequency of 
ILC3 in the small and large intestines (data not shown). 
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Figure 3.5. Generation of ILC3-specific DR3 genetic deletion 
model. (A) Generation of ILC3-specific DR3 genetic deletion model. 
(B) Representative flow cytometry analysis of extracellular DR3 
expression on indicated mice in (A).  
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3.4.3  ILC3-specific DR3 signaling promotes barrier protection  
To evaluate a role for ILC3-intrinsic DR3 in experimental colitis, 
we exposed DR3ΔILC3 mice and their littermate controls to ad libitium 
2% DSS. Phenocopying DR3-deficient mice, DR3ΔILC3 mice lost 
significantly more weight (Figure 3.6A) and had more severe colitis 
histopathology (Figure 3.6B) than their littermate controls.  Flow 
cytometry analysis revealed lower production of IL-22 by ILC3s from 
DR3ΔILC3 mice compared to littermates controls (Figure 3.6C).  Similar 
to DR3-deficient animals, treatment with rIL-22 completely rescued 
DR3ΔILC3 mice (Figure 3.6A).  Since IL-22 is critical for inducing 
intestinal epithelial cell production of antimicrobial peptides79 and 
acute phase reactants66, we evaluated Reg3g and Saa1 expression in 
intestinal epithelial cells isolated from these mice (Figure 3.6D).  
Reduced expression of both Reg3g and Saa1 reflects the decreased 
production of IL-22 in DR3ΔILC3 mice during colitis compared to 
littermate controls.  
To test the role for DR3 in an alternate colitis model, we used 
the Citrobacter rodentium infectious colitis model, which is dependent 
on ILC3 during the acute response75. Similar to the response in DSS 
colitis, DR3ΔILC3 mice lost significantly more weight and had reduced 
survival than their littermate controls (Figure 3.7).  Collectively, these 
experiments demonstrate a key role for cell-intrinsic DR3 in regulating 
ILC3 production of IL-22 and protection from acute experimental 
colitis. 
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Figure 3.6. ILC3 expression of DR3 plays an essential role in 
regulating IL-22-dependent protection from experimental colitis.  
(A) Body weights of 2% DSS-treated DR3flox/flox and DR3ΔILC3 
littermate mice compared with DR3ΔILC3 mice treated with rIL-22 i.v. on 
days 4 and 6 of DSS treatment (with n = 13, 13, 4 mice/group for 
DR3flox/flox, DR3ΔILC3-, and  DR3ΔILC3 + rIL-22, respectively). (B) 
Representative colonic histology and colonic scoring from DR3flox/flox 
and DR3ΔILC3 littermate mice following 2% DSS treatment for 7 days 
(analyzed in A). (C) Percentage of colonic Lin-CD127+CD90+RORγt+ 
ILC3s producing IL-22 from 2% DSS-treated DR3flox/flox and DR3ΔILC3 
littermate mice 9 days after starting DSS treatment (n = 4-5 
mice/group; LPMC were stimulated ex vivo with rIL-23 and brefeldin 
for 4 hours before intracellular IL-22 staining). (D) Epithelial cell 
REG3γ and SAA1 mRNA expression in 2% DSS-treated DR3flox/flox 
and DR3ΔILC3 littermate mice 9 days after starting 2% DSS treatment 
(n = 4 mice/group). Data in (A) are mean ± s.e.m. and were analyzed 
by ANOVA with multiple comparisons; data in (C, D) are mean ± s.e.m  
and were analyzed by two-tailed Student’s t-test; *P<0.05, **P<0.01.  
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Figure 3.6. ILC3 expression of DR3 plays an essential role in 
regulating IL-22-dependent protection from experimental colitis.    
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Figure 3.7. ILC3 expression of DR3 protects from Citrobacter 
rodentium colitis.  (A, B) Body weights (A) and survival curves (B) of 
C. rodentium-infected DR3flox/flox and DR3ΔILC3 littermate mice (n = 5, 4  
mice/group, respectively). Data in (A) are mean ± s.e.m. and analyzed 
by Mann-Whitney test; data in (B) were analyzed by Log-rank (Mantel-
Cox) test; *P<0.05. 
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3.4.4  TL1A/IL-23 synergize via p38 MAPK to mediate barrier 
protection  
To investigate the mechanism for TL1A regulation of ILC3-
derived IL-22, we sorted Lin- CD127+ IL-23RGFP ILC3s from the small 
intestinal lamina propria and stimulated ex vivo with either 
recombinant TL1A, IL-23, or TL1A+IL-23.  Although both IL-23 and 
TL1A induce IL-22 transcription, concomitant stimulation with both IL-
23 and TL1A induced a robust synergistic response in IL-22 (Figure 
3.8A).  To confirm that TL1A synergy signaled through its 
monogamous receptor DR3, we sorted ILC3 from DR3-deficient mice 
or WT littermates.  TL1A synergy with IL-23 required ILC3 expression 
of DR3 (Figure 3.8B).  
Distinct ILC3 subsets expressing either the natural cytotoxicity 
receptor NKp46 (called NCR+ ILC3) or chemokine receptor 6 (CCR6) 
(called lymphoid tissue-inducer-like ILC3) share significant functional 
overlap in the intestine.72 Surface DR3 expression was equivalent 
across all ILC3 subsets (Figure 3.9A).  Additionally, ex vivo TL1A 
stimulation of sorted intestinal ILC3 revealed synergistic induction of 
IL-22 in all subsets (Figure 3.9B) 
In monocyte-derived macrophages, TL1A synergy with 
muramyl dipeptide to induce inflammatory cytokines requires 
autocrine, non-canonical caspase-8-dependent IL-1b80.  To test the 
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potential contribution of autocrine IL-1b by ILC3, we sorted ILC3s from 
WT and IL1R-deficient mice.  While IL1R was required for both IL-1b-
dependent induction of IL-22, the TL1A/IL23 synergy remained intact 
suggesting that autocrine IL-1b is dispensable for the TL1A/IL23 
synergistic enhancement of IL-22 (Figure 3.10).   
In contrast to the non-canonical caspase pathway used in 
macrophages, conventional signaling downstream of DR3 can occur 
through mitogen-activated protein kinase (MAPK) or NF-kB 
pathways81.  To evaluate the role for these signaling pathways in 
ILC3, we profiled protein phosphorylation by flow cytometry.  Our 
results revealed significant phosphorylation of IkBa and p38-MAPK 
but not ERK following TL1A stimulation of sorted intestinal ILC3 
(Figure 3.11A).  To test the dependence on MAPK or NF-kB signaling, 
we sorted ILC3 and pre-treated with soluble inhibitors prior to ex vivo 
TL1A stimulation.  Although the NF-kB inhibitor NBD did not affect IL-
22 production, pre-treatment with TAK1 or p38 MAPK inhibitors (5Z-7-
Oxozeaenol and SB203580, respectively) completely blocked TL1A 
and IL-23 synergistic induction of IL-22 (Figure 3.11B).  To evaluate a 
physiologic role for IL-23 and TL1A synergy in vivo, we generated 
DR3- and IL23R-deficient double knock-out mice (DR3-/-IL23R-/-).  
DR3-/-IL23R-/- mice showed significantly reduced survival following 
acute DSS-induced colitis (Figure 3.12).  Collectively, these data 
57 
 
reveal the direct synergy of these IBD-linked pathways in regulating 
ILC3 production of effector cytokines and protection from acute colitis. 
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Figure 3.8. TL1A potently and selectively synergizes with IL-23 
via DR3 to induce IL-22 production in ILC3 in vitro. (A, B) Sorted 
ILC3 from the intestinal lamina propria from WT or DR3-/- mice were 
stimulated ex vivo with media (-), rIL-23 and/or rTL1A. Quantitative 
PCR (A) or intracellular cytokine staining for IL-22 (B) was performed 
after 18h stimulation. Data in (A) are mean ± s.e.m; ***P<0.001; two-
tailed Student’s t-test with Bonferroni correction.  
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Figure 3.9. TL1A synergizes with IL-23 to induce IL-22 production 
in ILC3 subsets. (A) ILC3 (Lin-CD127+IL23R-GFP+) subsets were 
evaluated for extracellular DR3 expression by flow cytometric 
analysis. (B) IL-22 production by sorted ILC3 subsets was measured 
by intracellular flow cytometry after 18h stimulation. Brefeldin was 
added to the cultures 4h before intracellular cytokine staining.  
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Figure 3.10. TL1A synergy with IL-23 is independent of IL1R. IL-22 
production by sorted ILC3 from WT or IL1R-/- mice after 18h 
stimulation with media, rIL-1b, rTL1A, or rIL-23 (or in combinations).  
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Figure 3.11. TL1A synergizes with IL-23 via p38-MAPK to induce 
IL-22 production in ILC3 in vitro. (A) Intracellular phosphoflow 
analysis was performed on sorted ILC3 for phosphorylation of p38-
MAPK, ERK and IkBa 30 minute following stimulation. (B) Sorted ILC3 
were stimulated for with r23 and rTL1A in the presence of soluble 
inhibitors. IL-22 production was evaluated by ELISA. Data in (B) are 
mean ± s.e.m; ***P<0.001; two-tailed Student’s t-test with Bonferroni 
correction.  
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Figure 3.12. TL1A potently synergizes with IL-23 to protect from 
experimental colitis. (A) Survival curves of WT, DR3-/-, IL23R-/- and 
DR3-/-IL23R-/- mice following 7 day treatment with 2% DSS. Data in are 
compiled from two independent experiments (with n = 26, 18, 7, and 4 
mice/group for WT, DR3-/-, IL23R-/- and DR3-/-IL23R-/- , respectively). 
Data in (A) are **P<0.01; Log-rank (Mantel-Cox) test. 
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3.5 DISCUSSION 
Our results in Chapter 2 shed light on the mechanisms 
underlying how CX3CR1+ MNP-derived TL1A promotes barrier 
protection during acute inflammation. Furthermore, our data offer 
insights into how TL1A protects from IBD-associated microbes, a 
potentially evolutionary trait that evolved to protect hosts from 
pathogenic intestinal infections. These experiments focused on the 
cellular source of TL1A, identifying lamina propria MNPs as the 
dominant producer of intestinal TL1A, but how TL1A regulates cellular 
effector functions had not been thoroughly explored.  
Here, using cell-specific genetic deletion models, we evaluated 
the contribution of this critical IBD-linked genetic pathway in regulating 
mucosal innate immunity during acute colitis.  Our data reveal a 
critical role for ILC3-specific DR3 acting synergistically with IL23R 
signaling in promoting mucosal healing in acute colitis. In vitro, DR3 
signaling on ILC3 was dependent on TAK1 and p38-MAPK signaling. 
In vivo, mice with mice with a double deletion of DR3 and IL23R  
(DR3-/- IL23R-/-) had decreased survival compared to mice with single 
deletions in either DR3 or IL23R, highlighting a synergistic role for 
DR3/IL23R signaling in promoting mucosal healing in vivo.  
Previous studies have focused predominantly on TL1A 
regulation of the adaptive immune system, and in particular T cells, 
our data demonstrate that during acute colitis, TL1A promotes barrier 
protection and mucosal healing via the regulation of ILC3s. A recent 
study reported that during acute colitis, TL1A was critical for promoting 
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mucosal healing via Foxp3+ Tregs32. Although we did not see changes 
in T cell numbers, subsets or cytokine production, our data are not 
entirely discordant with these findings since we looked at the early 
stages of acute colitis (days 7-9), whereas other studies noted T cell 
differences during the wound healing phase (days 10-22), but did not 
report significant changes during the earlier colitis stages. Here, I 
propose a revised model in which TL1A acts as a critical regulator of 
innate immunity during the early stages of colitis but can modulate the 
adaptive immune system during the recovery/wound healing stages of 
colitis.  
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CHAPTER FOUR: TL1A ENABLES ILC3 CO-STIMULATION OF T 
CELLS VIA OX40L 
4.1 ABSTRACT 
In previous chapters, we demonstrated an essential role for 
CX3CR1+ MNP-derived TL1A in promoting mucosal barrier protection 
during acute colitis. However, the mechanisms of how TL1A alters 
ILC3 effector functions to regulate effector T cell functions during 
chronic colitis are not known. Here, we used RNA-seq analysis to 
identify TL1A-dependent upregulation of the co-stimulatory molecule 
OX40L on ILC3, which enabled ILC3 to co-stimulate antigen-specific T 
cells proliferation in vitro. This data suggest a revised model in which 
inducible ILC3 expression of OX40L co-stimulation may trigger local T 
cell activation. 
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4.2 INTRODUCTION 
Group 3 innate lymphoid cells (ILC3) are an emerging class of 
innate lymphocytes that play a critical role in regulating mucosal 
homeostasis. In response to environmental triggers, in particular the 
cytokines IL-23 and IL-1b, ILC3 produce robust amounts of IL-22 and 
play an important role in maintaining intestinal barrier integrity and 
promoting mucosal healing—a major clinical endpoint in IBD24. Co-
localization of ILC3 with CX3CR1+ mononuclear phagocytes (MNPs) in 
the lamina propria enables rapid regulation of ILC3 effector cytokines 
to reinforce barrier immunity and mucosal healing40. Both mouse and 
human ILC3s express Death Receptor 3 (DR3), the monogamous 
receptor for TL1A, on its surface, with TL1A stimulation promoting 
ILC3 proliferation76 and cytokine production in vitro24; however, the 
role for TL1A in regulating ILC3 function in intestinal homeostasis, and 
its potential contribution to IBD pathophysiology, remains unknown.   
 Beyond reinforcing the intestinal barrier via effector cytokines, 
ILC3 have been reported to play an important role in the regulation of 
the of adaptive immunity82–85. In the previous chapter, we identified a 
pathogenic role for TL1A during chronic colitis. In a chronic T cell 
transfer model, ILC3-specific DR3 signaling promoted the generation 
of T-bet+ T cells in vivo. However, how ILC3 regulate T cell effector 
function via DR3 is currently unknown. To identify novel targets of 
TL1A on ILC3, we performed RNA-seq analysis of TL1A-stimulated 
ILC3, revealing an upregulation of the co-stimulatory molecule OX40L 
upon TL1A stimulation. In ILC3:T cell co-culture assays, TL1A 
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stimulation enabled MHCII+ ILC3 to co-stimulate OTII antigen-specific 
T cells in vitro, which was dependent on DR3 signaling, antigen 
presentation by MHC Class II and the costimulatory molecule OX40L, 
but not other co-stimulatory molecules like ICOSL. This data suggest 
a revised model in which inducible ILC3 expression of OX40L co-
stimulation may trigger local T cell activation. 
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4.3 METHODS 
Mice. C57BL/6, Rorc-cre, and OT-II mice were purchased from The 
Jackson Laboratory. Il23rGFP mice were obtained from M. Oukka77.  
MHCIIDILC3 mice were obtained from Gregory Sonnenberg86. 
Generation of Dr3flox/flox mice is previously described78. OX40Lflox/flox 
mice were obtained from David Withers87. All vertebrate work was 
approved by the IACUC at Weill Cornell Medicine. 
 
Antibodies and flow cytometry. Staining of cells was performed with 
the following antibodies: 
Table 4.1. Flow cytometry antibodies used in chapter 4. 
Species Target Fluorophore Clone Manufacturer 
Mouse CD3 FITC 145-2C11 eBioscience 
Mouse CD4 eFluor780 RM4-5 eBioscience 
Mouse CD5 PE 53-7.3 eBioscience 
Mouse CD45.1 APC A20 eBioscience 
Mouse CD90.2 efluor450  53-2.1 eBioscience 
Mouse MHCII Alexa700  M5/114.15.2 eBioscience 
Mouse CD19 FITC MB19-1 eBioscience 
Mouse CD11b eFluor780  M1/70 eBioscience 
Mouse CD11c PE-Cy7 N418 eBioscience 
Mouse CD103 APC 2E7 eBioscience 
Mouse TCRgd FITC 11-5711-82 eBioscience 
Mouse KLRG1 PE 2F1 eBioscience 
Mouse NKp46 eFluor710  29A1.4 eBioscience 
Mouse OX40L APC RM134L eBioscience 
Mouse ICOSL  eFluor660 HK5.3 eBioscience 
Mouse CD127 PE-Cy7  A7R34 BioLegend 
Mouse CCR6 BV421 29-2L17 BioLegend 
Mouse DR3 PE 4C12 BioLegend 
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Dead cells were excluded using the Live/Dead fixable aqua dead cell 
stain kit (Invitrogen). Intracellular cytokine staining was performed 
according to the manufacturer’s protocol (Cytofix/Cytoperm buffer set; 
BD) and transcription factor staining for was performed according to 
manufacturer’s protocol (Intracellular Fixation and Permeabilization kit; 
eBioscience). Flow cytometry was performed with a BD LSRFortessa 
and analyzed with FlowJo software (Tree Star).  
 
Preparation of LPMC. Mouse intestines were washed in PBS and 1 
mM DTT with 30 mM EDTA, and then digested in collagenase 8 
(Sigma-Aldrich) and DNase-containing media with 10% fetal bovine 
serum. Digested material was passed through a cell strainer and 
separated on a discontinuous 40%/80% Percoll gradient. 
 
Co-culture assays. For antigen-specific T-cell proliferation assays, 
2x105 sort-purified, CFSE-labeled naïve CD4+ T-cells from OTII 
transgenic mice were co-cultured with either 2.5x104 sort-purified ILC3 
from IL23RGFP/wt mice or 2x104 MHCII+CD11c+CD11b+ MNPs, with 
20ug/mL OVA peptide (OVA 323-339; InvivoGen) and 200ng/mL 
rTL1A, as indicated, in a 96-well flat bottom plate for six days. For co-
stimulatory blocking assays, ILC3/T cell co-cultures were blocked with 
20ug/mL anti-mouse ICOSL antibody (LEAF purified anti-mouse 
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CD275; BioLegend) or 15ug/mL anti-mouse OX40L antibody (Biotin 
anti-mouse CD252; BioLegend).  
 
RNA-seq analysis. Mouse RNA-Seq data was aligned to the mm9 
assembly of the mouse genome using the STAR aligner1. Read 
counts for genes across all BAM files were computed using the 
HTSeq software2. Differential analysis of RNA-Seq samples utilized 
the DESeq package for gene expression analysis3. False discovery 
rate correction of P-values used for all bioinformatics analyses of this 
study utilized the Benjamini-Hochberg procedure4. Heatmap clustering 
and production was done using the heatmap function within the NMF 
package in R5. Principal components analysis plots were visualized 
using the ggbiplot package in R.  
 
Statistical analysis. Statistical analysis was performed in GraphPad 
Prism or R software. Results represent mean ± s.e.m. and were 
analyzed by unpaired Student’s t-test or one-way ANOVA, as 
indicated in the figure legends. Given that mouse experiments 
required littermate controls and complex genotyping, experimental 
group allocation was not blinded. No relevant exclusion criteria were 
applied.  
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4.4 RESULTS 
4.4.1  TL1A induces co-stimulatory molecules on ILC3 
To identify novel genes and pathways regulated by TL1A, we 
performed RNA-seq of TL1A-stimulated intestinal ILC3.  ILC3 were 
sort-purified from IL23RGFP/WT mice and stimulated for 18 hours with or 
without recombinant TL1A (Figure 4.1A).  In addition to induction of 
Csf2 and Il22, RNA-seq analysis revealed significant induction of the 
co-stimulatory molecules OX40L and ICOSL following TL1A 
stimulation (Figure 4.1B), which was confirmed by quantitative PCR of 
its gene Tnfsf4 and flow cytometric analysis of surface expression of 
OX40L (Figure 4.1C). Furthermore, TL1A stimulation of sort-purified 
ILC3 revealed upregulation of OX40L across all ILC3 subsets (Figure 
4.2). 
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Figure 4.1. TL1A induces ILC3 expression of OX40L in vitro. (A) 
Experimental design for sort-purified ILC3 from IL23RGFP/WT mice 
treated with media or rTL1A for 18 h prior to RNA-seq analysis. (B) 
Scatterplot of global gene expression profiles of media- or rTL1A-
stimulated sorted Lin-CD127+IL23RGFP+ ILC3 from IL23RGFP/WT mice. 
Red and blue dots indicate significantly up- or down-regulated genes, 
respectively, after FDR correction for multiple hypothesis testing. (C) 
ICOSL and OX40L surface protein in sorted Lin-CD127+IL23RGFP+ 
ILC3 from IL23RGFP/WT mice stimulated for 18h with rTL1A or media 
alone. Data in C are mean ± s.e.m and were analyzed by two-tailed 
Student’s t-test; ***P<0.001.    
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Figure 4.2. TL1A induces OX40L expression across all ILC3 
subsets. (A) Sorted Lin-CD127+IL23RGFP+ ILC3 from the intestinal 
lamina propria of IL23RGFP/WT mice were stimulated ex vivo with media 
or rTL1A for 18 hours and extracellular OX40L levels were quantified 
in ILC3 subsets by flow cytometry. 
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4.4.2  TL1A enables ILC3 co-stimulation of OTII transgenic T 
cells in vitro 
Previous studies have shown that MHCII+ ILC3 lacking surface 
expression of classical co-stimulatory molecules negatively regulate T-
cell responses to commensal bacteria86. To test if TL1A-induced 
expression of co-stimulation could promote antigen-specific T-cell 
responses, MHCII+ and MHCII- ILC3 were sort-purified from 
IL23RGFP/WT mice and co-cultured with CFSE-labeled naïve OTII CD4+ 
T-cells in the presence or absence of OVA peptide or recombinant 
TL1A stimulation (Figure 4.3A). OVA peptide and TL1A stimulation of 
MHCII+ ILC3 induced multiple rounds of ovalbumin-specific T-cell 
proliferation, similar to the proliferative levels seen in OVA-loaded 
dendritic cells (Figure 4.3B).   
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Figure 4.3. TL1A stimulation of MHCII+ ILC3 enables ILC3 co-
stimulation of CD4+ T cells. (A) Experimental design for ILC3:T cell 
co-culture assay. (B) Sort-purified, CFSE-labeled CD4+ T-cells from 
OT-II transgenic mice were cultured for 6 days with sort-purified 
MHCII+ DCs, MHCII- ILC3 or MHCII+ ILC3, from either with media 
alone, OVA peptide, or OVA peptide and rTL1A, as indicated. (C) 
Quantification of antigen-specific T cell proliferation from (B). Data in 
C are mean ± s.e.m and were analyzed by Student’s t-test; 
****P<0.0001, ns= not significant. 
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4.4.3  ILC3 co-stimulation of T cells is DR3-dependent 
To test the genetic dependency of DR3 in promoting TL1A-
induced ILC3 co-stimulation of antigen-specific T cells, sort-purified 
ILC3 from DR3ΔILC3 RAG2-/- or DR3flox/flox RAG2-/-  littermates were co-
cultured with sorted, CFSE-labeled OTII T cells in the presence of 
OVA and with/without TL1A stimulation (Figure 4.4A). In contrast, to 
the proliferation seen in co-cultures with WT ILC3, DR3-deficient ILC3 
did not induce proliferation of OTII T cells (Figure 4.4B). 
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Figure 4.4. TL1A stimulation of MHCII+ ILC3 enables DR3-
dependent co-stimulation of CD4+ T cells. (A) Experimental design 
for ILC3:T cell co-culture assay. (B) Sort-purified, CFSE-labeled CD4+ 
T-cells from OT-II transgenic mice were cultured for 6 days with sort-
purified ILC3, from either DR3flox/flox or DR3ΔILC3 mice with media 
alone, OVA peptide, or OVA peptide and rTL1A, as indicated. (C) 
Quantification of antigen-specific T cell proliferation from (B). Data in 
C are mean ± s.e.m and were analyzed by one-way ANOVA; 
***P<0.001, ****P<0.0001, ns= not significant. 
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4.4.4  OX40L blocking inhibits TL1A-mediated ILC3 co-
stimulation of T cells 
To evaluate the potential contribution of ICOSL and OX40L in 
promoting ILC3 co-stimulation of T-cells, ILC3s were cultured with 
CFSE-labeled naïve OTII CD4+ T-cells in the presence of OVA, 
recombinant TL1A, and a-OX40L or a-ICOSL blocking antibodies 
(Figure 4.5A). OX40L, but not ICOSL, blockade completely inhibited in 
vitro proliferation, suggesting a key role for OX40L co-stimulation in 
regulation ILC3-driven T-cell proliferation (Figure 4.5B,C).   
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Figure 4.5. OX40L blocking inhibits TL1A-mediated ILC3 co-
stimulation of CD4+ T cells. (A) Experimental design for ILC3:T cell 
co-culture assay. (B) Sort-purified, CFSE-labeled CD4+ T-cells from 
OT-II transgenic mice were cultured for 6 days with sort-purified ILC3 
in the presence of media alone, rTL1A, or with rTL1A plus co-
stimulatory molecule blocking antibodies. All samples received OVA 
peptide in culture. (C) Quantification of antigen-specific T cell 
proliferation from (B). Data in C are mean ± s.e.m and were analyzed 
by one-way ANOVA; ***P<0.001, ns= not significant. 
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4.4.5  Generation of ILC3-specific OX40L deletion genetic model 
To specifically test the importance of ILC3-intrinsic OX40L 
signaling in intestinal barrier immunity, we crossed mice with a loxP-
flanked Tnfsf4 (OX40Lflox/flox) to transgenic mice expressing the Cre 
recombinase from the RORgt promoter (Rorccre) on a RAG2-deficient 
background (called OX40LΔILC3) (Figure 4.6A).  Transcriptional and 
flow cytometric analysis revealed that OX40LΔILC3 mice lacked O40L 
expression on ILC3 after TL1A stimulation, confirming OX40L deletion 
(Figure 4.6B).   
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Figure 4.6. Generation of ILC3-specific OX40L genetic deletion 
model. (A) Generation of ILC3-specific OX40L genetic deletion 
model. (B) Representative flow cytometry analysis of extracellular 
OX40L expression in sort-purified ILC3 from indicated mice stimulated 
for 18 h with rTL1A.  
   
OX40Lfl/fl 
OX40LΔILC3 
OX40L 
%
 o
f m
ax
 
B 
OX40L
ΔILC3
 
Rorc
CRE
 x OX40L
flox/flox
 x Rag2
-/-
 
A 
83 
 
4.4.6 ILC3 co-stimulation of T cells is OX40L-dependent 
 To test the genetic dependency of OX40L in promoting TL1A-
induced ILC3 co-stimulation of antigen-specific T cells, sort-purified 
ILC3 from OX40LΔILC3 RAG2-/- or OX40Lflox/flox RAG2-/-  littermates were 
co-cultured with sorted, CFSE-labeled OTII T cells in the presence of 
OVA and with/without TL1A stimulation (Figure 4.7A). In contrast, to 
the proliferation seen in co-cultures with WT ILC3, OX40L-deficient 
ILC3 did not induce proliferation of OTII T cells (Figure 4.7B,C). 
Given the previous data showing that ILC3 co-stimulation was 
dependent on the co-stimulatory molecule OX40L, we hypothesized 
that, mechanistically, ILC3 were promoting T cell proliferation via 
antigen presentation via MHCII with OX40L being the dominant co-
stimulatory signal. To test the genetic dependency of antigen-
presentation in promoting TL1A-induced ILC3 co-stimulation of 
antigen-specific T cells, sort-purified ILC3 from MHCIIΔILC3 or MHCIIWT 
mice were co-cultured with sorted, CFSE-labeled OTII T cells in the 
presence of OVA and with/without TL1A stimulation (Figure 4.8A). In 
contrast, to the proliferation seen in co-cultures with WT ILC3, MHCII-
deficient ILC3 did not induce proliferation of OTII T cells (Figure 
4.8B,C). 
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Figure 4.7. TL1A stimulation of MHCII+ ILC3 enables OX40L-
dependent co-stimulation of CD4+ T cells. (A) Experimental design 
for ILC3:T cell co-culture assay. (B) ILC3 sorted from mice with a 
conditional deletion of OX40L (OX40LΔILC3) or littermate controls 
OX40Lflox/flox were stimulated with TL1A and co-cultured with sort-
purified, CFSE-labeled OTII CD4+ T cells for 6 days. All samples 
received OVA peptide in culture. (C) Quantification of antigen-specific 
T cell proliferation from (B). Data in C are mean ± s.e.m and were 
analyzed by one-way ANOVA; ***P<0.001, ns= not significant. 
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Figure 4.8. TL1A stimulation of ILC3 enables MHCII-dependent 
co-stimulation of CD4+ T cells. (A) Experimental design for ILC3:T 
cell co-culture assay. (B) ILC3 sorted from mice with a conditional 
deletion of MHCII (MHCIIΔILC3) or WT ILC3 (MHCIIWT) were stimulated 
with TL1A and co-cultured with sort-purified, CFSE-labeled OTII CD4+ 
T cells for 6 days. All samples received OVA peptide in culture. (C) 
Quantification of antigen-specific T cell proliferation from (B). Data in 
C are mean ± s.e.m and were analyzed by one-way ANOVA; 
***P<0.001, ns= not significant. 
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4.5 DISCUSSION 
 In the previous chapter, we identified a pathogenic role for 
TL1A during chronic colitis. In a chronic T cell transfer model, ILC3-
specific DR3 signaling promoted the generation of T-bet+ T cells in 
vivo. However, how ILC3 regulate T cell effector function via DR3 is 
currently unknown. Here, we used RNA-seq analysis to identify TL1A-
dependent upregulation of the co-stimulatory molecules on ILC3, 
which enabled ILC3 to co-stimulate antigen-specific T cells 
proliferation in vitro. Mechanistically, ILC3 co-stimulation of OTII T 
cells in vitro was dependent on DR3 signaling, antigen presentation by 
MHC Class II and the costimulatory molecule OX40L, suggesting that 
ILC3 co-stimulation of naïve T cells is dependent on ILC3 antigen 
presentation with both signal 1 and signal 2 present after TL1A 
stimulation. However, it remains to be explored whether the induction 
of these co-stimulatory molecules, and OX40L specifically, is unique 
to TL1A stimulation or if it can also be induced by other cytokines, like 
IL-1b or IL-23. Furthermore, whether ILC3 can co-stimulate antigen-
specific T cells via DR3 and OX40L in vivo, and any potential 
contribution to intestinal pathophysiological, remains unknown.  
The discovery of antigen processing and presentation by 
intestinal ILC3 highlights a central role for these cells in linking innate 
and adaptive immunity86.  Although splenic ILC3 can upregulate 
conventional co-stimulatory molecules CD80 and CD86 following IL-
1b stimulation88, the absence of these co-stimulatory molecules, even 
following stimulation, on intestinal ILC3 lead to a model in which they 
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limit bacteria-specific inflammatory T-cell responses in the gut89. By 
showing that TL1A induced expression of co-stimulatory molecule OX40L on 
the surface of MHCII+ ILC3 support in vitro proliferation of naïve antigen 
specific T cells, our data suggest a revised model in which inducible ILC3 
expression of OX40L co-stimulation may trigger local T cell activation. 
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CHAPTER FIVE: DR3-OX40L AXIS PROMOTES ILC3 CO-
STIMULATION OF T CELLS IN VIVO 
5.1 ABSTRACT 
Previous studies have suggested a pathogenic role for chronic 
TL1A expression in IBD. However, the mechanisms by which TL1A 
contributes to chronic colitis are not known. Here, we report an 
essential role for ILC3-intrinsic DR3-OX40L axis in regulating T cell 
function in vivo. During colitis, ILC3 upregulated OX40L in a DR3-
dependent manner. In contrast to this protective role in acute colitis, 
colitis-induced DR3-dependent expression of OX40L enabled MHCII+ 
ILC3 to co-stimulate dietary and microbial antigen-specific T cell 
proliferation and exacerbate chronic T cell-dependent colitis. Colonic 
biopsies from IBD patients revealed increased OX40L on ILC3 
compared to healthy controls, highlighting the conserved TL1A-OX40L 
ILC3 axis in IBD. These data reveal a pro-inflammatory role for the 
ILC3 DR3-OX40L axis in chronic T cell colitis and a novel role in the 
regulation of antigen-specific T cells in vivo. 
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5.2 INTRODUCTION 
MHCII+ ILC3s play in a central role in regulating T cell 
homeostasis in the intestine84. Previous studies have reported that at 
the steady state, MHCII+ ILC3 lack the expression of co-stimulatory 
molecules and can limit T cell responses to commensal antigens via 
anergy84,86, suggesting a protective role for ILC3 in limiting the 
generation of autoreactive T cells. In the previous chapter, we 
reported that TL1A stimulation induced the expression of the co-
stimulatory molecule OX40L, which enabled ILC3 to co-stimulate 
antigen-specific T cells in vitro; the co-stimulatory capacity of ILC3 
was dependent on TL1A signaling via DR3, antigen presentation by 
MHCII, and the co-stimulatory molecule OX40L. However, the 
functional role for ILC3-intrinsic OX40L in regulating T cell function in 
vivo has not been explored. 
Here, using genetic mouse models with selective deletion of 
DR3 and OX40L on ILC3, we evaluated a role of this critical IBD-
linked axis in regulating T cell-mediated mucosal immunity.  Our data 
reveal a central role for the DR3-OX40L axis on ILC3 in regulating 
dietary and microbial antigen-specific T cell proliferation in vivo and a 
functional role in promoting chronic T cell-dependent colitis. 
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5.3 METHODS 
 
Mice. C57BL/6, Rorc-cre, and OT-II mice were purchased from The 
Jackson Laboratory. Il23rGFP mice were obtained from M. Oukka77.  
Dr3flox/flox mice is previously described78. OX40Lflox/flox mice were 
obtained from David Withers87. Helicobacter hepaticus transgenic 
TCR mice were obtained from D. Littman90. Generation of All 
vertebrate work was approved by the IACUC at Weill Cornell 
Medicine. 
 
Human IBD subjects. A cohort of patients was evaluated for IBD at 
the Jill Roberts Center for IBD under Institutional Review Board–
approved protocol (1103011578) at Weill Cornell Medicine (WCM). 
Healthy control patients presented with abdominal pain but had 
normal endoscopic results; IBD patients were defined as having 
endoscopic inflammation with a history of ulcerative colitis or Crohn’s 
disease. All endoscopic biopsies were taken from the colon. 
Endoscopic biopsies from healthy control and IBD patients were 
transported in ice cold PBS and processed as previously reported 
(JEM, Longman).  
 
 
Antibodies and flow cytometry. Staining of cells was performed with 
the following antibodies: 
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Table 5.1. Flow cytometry antibodies used in chapter 5. 
Species Target Fluorophore Clone Manufacturer 
Mouse CD3 FITC 145-2C11 eBioscience 
Mouse CD4 eFluor780 RM4-5 eBioscience 
Mouse CD5 PE 53-7.3 eBioscience 
Mouse CD45.1 APC A20 eBioscience 
Mouse CD90.2 efluor450  53-2.1 eBioscience 
Mouse MHCII Alexa700  M5/114.15.2 eBioscience 
Mouse CD19 FITC MB19-1 eBioscience 
Mouse CD11b eFluor780  M1/70 eBioscience 
Mouse CD11c PE-Cy7 N418 eBioscience 
Mouse CD103 APC 2E7 eBioscience 
Mouse TCRgd FITC 11-5711-82 eBioscience 
Mouse KLRG1 PE 2F1 eBioscience 
Mouse OX40L APC RM134L eBioscience 
Mouse CD127 PE-Cy7  A7R34 BioLegend 
Mouse CCR6 BV421 29-2L17 BioLegend 
Mouse DR3 PE 4C12 BioLegend 
Mouse RORgt PE B2D eBioscience 
Mouse T-bet e660 eBio4B10 eBioscience 
Mouse Foxp3 e450 FJK-16s eBioscience 
Mouse IL-22 APC IL22JOP eBioscience 
Mouse TL1A e710 Tandys1a eBioscience 
Human CD14 PE 61D3 eBioscience 
Human CD14 Alexa700 63D3 eBioscience 
Human 
HLA-
DR Alexa700 LN3 eBioscience 
Human TL1A e710 Tandys1a eBioscience 
Human CD45 APC 2D1 eBioscience 
Human CD3 eFluor780 UCHT1 eBioscience 
Human CD19 Alexa700 HIB19 eBioscience 
Human CD127 PE-Cy7 eBioRDR5 eBioscience 
Human CD117 efluor450 104D2 eBioscience 
Human OX40L PE 11C3.1 BioLegend 
Human CD5 eFluor780 UCHT1 BioLegend 
Human ST2L FITC B4E6 mdbioproducts 
Human CD11c Alexa700 3.9 Invitrogen 
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Dead cells were excluded using the Live/Dead fixable aqua dead cell 
stain kit (Invitrogen). Intracellular cytokine staining was performed 
according to the manufacturer’s protocol (Cytofix/Cytoperm buffer set; 
BD) and transcription factor staining for was performed according to 
manufacturer’s protocol (Intracellular Fixation and Permeabilization kit; 
eBioscience). Flow cytometry was performed with a BD LSRFortessa 
and analyzed with FlowJo software (Tree Star).  
 
Preparation of LPMC. Mouse intestines were washed in PBS and 1 
mM DTT with 30 mM EDTA, and then digested in collagenase 8 
(Sigma-Aldrich) and DNase-containing media with 10% fetal bovine 
serum. Digested material was passed through a cell strainer and 
separated on a discontinuous 40%/80% Percoll gradient. 
 
Colitis models. To induce chemical colitis in mice, 2% DSS (w/v) 
(M.W. 40,000-50,000; Affymetrix) was added to sterile drinking water 
and administered ad libitum for 7 days. After 7 days, DSS was 
replaced with normal drinking water. For T-cell transfer colitis, 5x105 
CD4+ CD45RBhigh CD25- CD62L- T-cells were transferred i.p. into 
OX40LΔILC3 RAG2-/- or OX40Lflox/flox RAG2-/- mice or in a separate 
experiment, into DR3ΔILC3 RAG2-/- or DR3flox/flox RAG2-/- mice, as 
indicated in the figure legends.  To induce infectious colitis, 
Helicobacter hepaticus were cultured as previously described90; for 
oral infection, mice were orally gavaged with Helicobacter hepaticus 
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every four days for a total of two inoculations, as previously 
described90. For all colitis experiments, mice were monitored daily 
weight loss, rectal bleeding, diarrhea and survival throughout the 
experiments. For all colitis experiments, mice were monitored daily 
(DSS) or weekly (T-cell transfer) for weight loss, rectal bleeding, 
diarrhea and survival throughout the experiments. 
Antigen-specific T-cell transfer. For OVA-specific T cell transfer 
experiments, CD45.2+ OX40Lflox/flox and CD45.2+ OX40LΔILC3 were fed 
ad libitum 1% ovalbum and to 2% dextran sodium sulfate for five days 
prior to the transfer of 5x105 CFSE-labeled CD45.1+ CD3+CD4+ Va2 
OTII T-cells (i.p.) from OVA TCR transgenic mice. Transferred T-cells 
were analyzed seven days post-transfer. For Helicobacter hepaticus-
specific T cell transfer experiments, mice were orally gavaged with 
Helicobacter hepaticus every four days for a total of two inoculations, 
as previously described90; eight days post Helicobacter hepaticus 
inoculation, 3x104 sort-purified naïve CD3+CD4+CD44loCD62LhiCD25-
Vb6+ T cells from CD45.1+ Helicobacter hepaticus transgenic TCR 
mice were administered by retro-orbital injection into CD45.2+ 
OX40Lflox/flox and CD45.2+ OX40LΔILC3 mice. After fourteen days, the 
CD45.1+ Helicobacter hepaticus-specific T cells were analyzed by 
flow cytometry. 
 
Statistical analysis. Statistical analysis was performed in GraphPad 
Prism or R software. Results represent mean ± s.e.m. and were 
analyzed by unpaired Student’s t-test or one-way ANOVA, as 
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indicated in the figure legends. Given that mouse experiments 
required littermate controls and complex genotyping, experimental 
group allocation was not blinded. No relevant exclusion criteria were 
applied.  
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5.4 RESULTS 
5.4.1 ILC3 upregulation of OX40L during colitis is DR3-
dependent 
To evaluate the ability of ILC3 to express OX40L in vivo during 
colitis, we performed flow cytometry on lamina propria ILC3 at steady 
state and following DSS-induced colitis.  Although low OX40L was 
seen on ILC3 at steady state, colitis induced robust expression of 
OX40L (Figure 5.1A).   Expression of OX40L on ILC3 following DSS-
induced colitis in DR3ΔILC3 mice was significantly reduced compared to 
DR3flox/flox littermate controls, revealing a key role for DR3 in ILC3 
expression of OX40L in vivo (Figure 5.2B).  
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Figure. 5.1. TL1A induces ILC3 expression of OX40L during 
colitis in vivo. (A) OX40L expression on Lin-CD127+ RORgt+ ILC3 at 
the steady-state or following 2% DSS-induced colitis. (E) OX40L 
expression on Lin-CD127+ RORgt+ ILC3 from DR3flox/flox and DR3ΔILC3 
littermate mice following 2% DSS-induced colitis (n = 4 mice/group). 
Data in (B) are mean ± s.e.m and were analyzed by two-tailed 
Student’s t-test; **P<0.01.   
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5.4.2  Human IBD patients upregulate OX40L on ILC3 during 
colitis 
To determine if ILC3 express OX40L during inflammatory bowel 
disease (IBD), we profiled ILC3 from human intestinal biopsy samples.  
Lin- CD127+ c-kit+ ILC3 from patients with active IBD showed 
significantly higher levels of surface OX40L expression (Figure 5.2).  
Collectively, these results reveal TL1A- and colitis-dependent OX40L 
expression by intestinal ILC3 in mouse and human. 
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Figure 5.2. Human IBD patients upregulate ILC3 expression of 
OX40L during active colitis. (A) Human OX40L expression on Lin-
CD127+c-KIT+ ILC3 from colonic biopsies of healthy patients or IBD 
patients with active inflammation (n=6 patients/group). Data in (A) are 
mean ± s.e.m and were analyzed by two-tailed Student’s t-test; 
**P<0.01.   
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5.4.3  ILC3-specific OX40L deletion attenuates chronic T cell 
transfer colitis 
To evaluate the potential role for ILC3 expression of OX40L in 
a chronic colitis model, we used the transfer T cell colitis model by 
transferring sort-purified CD4+CD45RBhigh naïve T-cells from WT mice 
into OX40LΔILC3 RAG2-/- or OX40Lflox/flox RAG2-/-  littermate mice 
(Figure 5.3A).  The characteristic weight loss consistent with chronic T 
cell-mediated colitis developed within 4 weeks in the OX40Lflox/flox 
RAG2-/-  littermate controls (Figure 5.3B); however, in contrast to the 
effects seen in acute models, OX40LΔILC3 RAG2-/- were significantly 
protected (Figure 5.3B). Analysis of colonic tissue in these mice 
revealed decreased histopathologic damage in the OX40LΔILC3 mice 
compared to littermate controls (data not shown) and transferred T-
cells revealed an expansion of IFN-g+ CD4+ T cells in the OX40Lflox/flox 
RAG2-/-  controls compared to OX40LΔILC3 RAG2-/-  mice (Figure 5.4B).  
Thus, in contrast to the protective role in acute colitis, these data 
reveal a pro-inflammatory role for ILC3-intrinsic OX40L in chronic T 
cell colitis. 
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Figure 5.3. ILC3-specific deletion of OX40L attenuates chronic 
transfer T cell colitis and prevents expansion of pro-inflammatory 
colonic Th1 cells. (A) Experimental design for induction of transfer T 
cell colitis in OX40Lflox/flox RAG2-/- or OX40LΔILC3 RAG2-/- littermate 
mice. (B-D) Analysis of OX40LΔILC3RAG2-/-  and OX40Lflox/floxRAG2-/- 
littermate mice following adoptive transfer of CD4+CD45RBhigh T-cells 
for induction of T cell transfer colitis.  Body weights (B) and cytokine 
induction (C, D) from OX40LΔILC3RAG2-/-  and OX40Lflox/floxRAG2-/- 
littermate mice following adoptive transfer of CD4+CD45RBhigh T-cells 
(n = 8 mice/group); for (C), mice from (B) were euthanized on day 50 
and CD3+CD4+ T cell production of IFN-ɣ was analyzed by flow 
cytometry (n = 4 mice/group). Data in (B) are mean ± s.e.m and were 
analyzed by two-tailed Mann-Whitney test; data in (D) were analyzed 
two-tailed Student’s t-test;  *P<0.05. 
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5.4.4  ILC3-specific DR3 deletion attenuates chronic colitis 
In contrast to our findings for an essential role for TL1A and 
DR3 in protection from acute colitis, previous studies have suggested 
a pathogenic role for constitutive TL1A overexpression in IBD31. 
However, the mechanisms for TL1A-mediated intestinal damage 
during chronic colitis are unknown. Our previous RNA-seq analysis 
revealed that TL1A stimulation potently upregulated OX40L 
expression on ILC3 and our in vivo data using mouse colitis models 
demonstrated that ILC3-intrisic OX40L was essential for induction of T 
cell transfer colitis. Next, we asked if the ILC3-intrinsic DR3, which we 
have shown is essential for the upregulation of OX40L on ILC3, was 
important for mediating this OX40L-depndent T cell transfer colitis 
phenotype.  
To evaluate the potential dependence for ILC3-intrinsic DR3 in 
promoting chronic colitis , we used the transfer T cell colitis model by 
transferring sort-purified CD4+CD45RBhigh naïve T-cells from WT mice 
into DR3ΔILC3 RAG2-/- or DR3flox/flox RAG2-/-  littermates (Figure 5.4A).  
The characteristic weight loss (Figure 5.4B) and reduced survival 
(Figure 5.4C) consistent with chronic T cell-mediated colitis developed 
within 4 weeks in the DR3flox/flox RAG2-/-  littermate controls; however, 
in contrast to the effects seen in acute models, DR3ΔILC3 RAG2-/- were 
significantly protected. Analysis of colonic tissue in these mice 
revealed decreased histopathologic damage in the DR3ΔILC3 mice 
compared to littermate controls (Figure 5.4D) and transferred T-cells 
revealed an expansion of T-bet+ CD4+ T cells in the DR3flox/flox RAG2-/-  
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controls compared to DR3ΔILC3 RAG2-/-  mice (Figure 5.4E).  Thus, in 
contrast to the protective role in acute colitis, these data reveal a pro-
inflammatory role for ILC3-intrinsic DR3 in chronic T cell colitis. 
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Figure 5.4. ILC3-specific deletion of DR3 attenuates chronic 
transfer T cell colitis and prevents expansion of pro-inflammatory 
colonic Th1 cells. (A) Experimental design for induction of transfer T 
cell colitis in DR3flox/flox RAG2-/- or DR3ΔILC3 RAG2-/- littermate mice. (B-
D) Analysis of DR3flox/flox RAG2-/- or DR3ΔILC3 RAG2-/- littermate mice 
following adoptive transfer of CD4+CD45RBhigh T-cells to induce 
transfer T cell colitis.  Body weights (B), survival curves (C) and 
representative colonic histology (D) from DR3flox/flox RAG2-/- or 
DR3ΔILC3 RAG2-/- littermate mice adoptive transfer of CD4+CD45RBhigh 
T-cells; for (B), n = 6, 7 mice/group, respectively, pooled from two 
independent experiments; for (C), n = 8, 10 mice/group, respectively, 
pooled from three independent experiments. (E) Flow cytometric 
analysis of T-bet induction in transferred T-cells from DR3flox/flox RAG2-
/- or DR3ΔILC3 RAG2-/- littermate mice in (B) and (C). Data in (B) are 
mean ± s.e.m and were analyzed by two-tailed Mann-Whitney test.  
Data in (B) were analyzed by Log-rank (Mantel-Cox) test;  **P<0.01, 
***P<0.001. Data in (E) are mean ± s.e.m and were analyzed by two-
tailed Student’s t-test.  
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Figure 5.4. ILC3-specific deletion of DR3 attenuates chronic 
transfer T cell colitis and prevents expansion of pro-inflammatory 
colonic Th1 cells.  
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5.4.5  ILC3 OX40L generates intestinal T cells during colitis 
To investigate a role for ILC3 OX40L signaling in regulating 
intestinal T cell function, we analyzed T cell subsets in OX40LDILC3 and 
OX40Lflox/flox littermate mice. At the steady state, OX40LDILC3 and 
OX40Lflox/flox had similar levels of Th1 and Th17, but OX40LDILC3 had 
reduced regulatory T cell populations. Furthermore, under 
Helicobacter hepaticus-induced colitis, OX40LDILC3 mice had 
significant impairment in intestinal T-bet+ and Foxp3+ T cell 
populations. There were no differences in mesenteric lymph node or 
splenic T cell populations of OX40LDILC3 and OX40Lflox/flox mice (data 
not shown).  	
5.4.6  ILC3 OX40L promotes dietary and microbial antigen-
specific T cells 
Previous studies have reported that ILC3 negatively regulate 
commensal antigen-specific T cells via MHCII at the steady state86,89, 
but our in vitro data demonstrate that ILC3 can promote T cell effector 
function via OX40L co-stimulation; however, the a role for ILC3 OX40L 
co-stimulation of T cells in vivo has not been explored. To test the role 
for ILC3 expression of OX40L on dietary antigen-specific gut T-cells in 
vivo, sorted naïve CD45.1+ OTII cells were adoptively transferred into 
OX40LΔILC3 mice and littermate controls (Figure 5.5A).  Mice were 
exposed to DSS for 5 days (to induce OX40L) and provided ovalbumin 
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antigen ad lib.  One week following T-cell transfer, CD45.1+ CD4+ T 
cells were significantly lower in the mesenteric lymph node of 
OX40LΔILC3 mice compared to OX40Lflox/flox littermates (Figure 5.5B).   
 We next asked if ILC3 could regulate microbial antigen-specific 
T cells. A recent study has reported that Helicobacter hepaticus-
specific T cells are characterized by the dual expression of RORgt and 
Foxp390. Since OX40LΔILC3 mice were deficient in RORgt+Foxp3+ T 
cells during Helicobacter hepaticus-induced colitis, we investigated 
whether ILC3 OX40L was necessary for the generation of 
RORgt+Foxp3+ Helicobacter hepaticus-specific T cells. To test the role 
for ILC3 expression of OX40L on the generation of Helicobacter 
hepaticus-specific gut T-cells in vivo, OX40LΔILC3 and OX40Lflox/flox 
littermate mice were colonized with Helicobacter hepaticus for seven 
days before the transfer of congenically-marked, sort-purified naïve 
CD3+CD4+CD44loCD62LhiCD25-Vb6+ T cells from CD45.1+ 
Helicobacter hepaticus transgenic TCR mice (Figure 5.6A).  Fourteen 
days after transfer, CD45.1+ RORgt+Foxp3+ HH-Tg T cells were 
significantly lower in the large intestine of OX40LΔILC3 mice compared 
to their OX40Lflox/flox littermates (Figure 5.6B). However, there were no 
differences in  CD45.1+ RORgt+Foxp3+ T cells HH-Tg T cells in the 
mesenteric lymph node or spleens of OX40LΔILC3 and OX40Lflox/flox 
mice (data not shown).  
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Figure 5.5. TL1A stimulation of MHCII+ ILC3 enables OX40L-
dependent co-stimulation of CD4+ T cells. (A) Experimental design 
for transfer of CD45.1+ CD3+CD4+V⍺2+ OTII T-cells into CD45.2+ 
OX40Lflox/flox  or CD45.2+ OX40LΔILC3 mice treated with 2% DSS and 
ovalbumin for 5 days. (B) Flow cytometric analysis of CD45.1+ 
CD3+CD4+V⍺2+ OTII T-cells from (A) compiled over two independent 
experiments (n= 6-8 mice/group). Data in G are mean ± s.e.m and 
were analyzed by Student’s t-test; ***P<0.001. 
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Figure 5.6. ILC3 promote the generation of Helicobacter 
hepaticus-specific T cells via OX40L. (A) Experimental design for 
transfer of CD3+CD4+CD44loCD62LhiCD25-Vb6+ HH-Tg T cells from 
CD45.1+ Helicobacter hepaticus transgenic TCR mice into CD45.2+ 
OX40Lflox/flox  or CD45.2+ OX40LΔILC3 mice colonized for 7 days with 
Helicobacter hepaticus. (B) Flow cytometric analysis of transferred 
CD45.1+ HH-Tg and CD45.2+  endogenous T-cells from (A). (C) 
Quantification of transferred CD45.1+ HH-Tg and CD45.2+  
endogenous T-cells from (A-B) (n= 10 mice/group compiled over two 
experiments). Data in C are mean ± s.e.m and were analyzed by 
Student’s t-test; ns = not significant, *P<0.05, **P<0.01, ***P<0.001. 
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5.5 DISCUSSION 
 
In previous chapters, we demonstrated a protective role for 
MNP-derived TL1A and DR3 signaling on ILC3 during acute colitis. 
Here, our data demonstrate how ILC3-specific DR3 and OX40L 
signaling promotes chronic colitis via the regulation of pathogenic T-
bet+/IFN-g+ T cells.  This discovery offers mechanistic data on how the 
TL1A-OX40L axis serves as a critical link between the innate and 
adaptive immune systems via ILC3 regulation of T cells 
The discovery of antigen processing and presentation by 
intestinal ILC3 highlights a central role for these cells in linking innate 
and adaptive immunity86. Although splenic ILC3 can upregulate 
conventional co-stimulatory molecules CD80 and CD86 following IL-
1b stimulation88, the absence of these co-stimulatory molecules, even 
following stimulation, on intestinal ILC3 lead to a model in which they 
limit bacteria-specific inflammatory T-cell responses in the gut.89 Our 
data highlight the expression of OX40L by ILC3 in inflammatory colitis 
in mouse models and human IBD.  Specifically, during chemically-
induced DSS colitis, ILC3 upregulate surface OX40L in a DR3-
dependent manner. Similarly, mucosal biopsies form IBD patients 
demonstrate that human ILC3 also upregulate OX40L during active 
colitis. In vivo, mice with a ILC3 cell-specific deletion of either DR3 or 
OX40L were unable to support T cell transfer colitis, demonstrating 
that the DR3-OX40L axis plays a significant role in ILC3 regulation of 
111 
 
T cell effector functions in vivo. Lastly, our data demonstrate that ILC3 
can regulate both dietary and microbial antigen-specific T cells in vivo 
via OX40L. This data offer the exciting possibility that ILC3 may 
contribute to the generation of peripheral T cells that are autoreactive 
to intestinal microbial antigens. Whether TL1A or OX4OL contribute to 
this process, if true, and whether it contributes to the pathophysiology 
of IBD remains unknown.  
In humans, how  and/or if ILC3 regulate T cells in human 
remains to be explored. Specifically, do MNP TL1A or ILC3 OX40L 
levels correlate with Th1 T cells in the inflamed tissue of IBD patients? 
Do levels of TL1A or OX40L correlate with disease outcomes in these 
patients? These are valid questions that should be pursued in future 
studies. 
Expression of OX40L by ILC3 plays a critical role in regulating 
gut antigen-specific and effector T-cell responses.  These data, 
therefore, extend the model by which MHCII+ ILC3 regulate the gut T 
cell response, which may reflect OX40L-dependent regulatory 
responses under homeostatic conditions91. However, in IBD patients 
with genetic susceptibility or animal models of T-cell transfer colitis, 
ILC3 co-stimulation can support pathogenic, inflammatory T-cell 
activation. Further studies are needed to decipher the mechanisms of 
how TL1A alters ILC3 effector functions to regulate the adaptive 
immune system. 
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CHAPTER 6: DISCUSSION 
6.1  Summary 
Genetic studies have linked TNFSF15 polymorphisms and its 
protein TL1A with IBD, but the functional role of TL1A in tissue 
homeostasis and intestinal inflammation is not known. Previous 
studies had pointed at a pathogenic role for TL1A, particularly via the 
regulation of T cells at epithelial barrier sites, but more recent studies 
had implicated TL1A in the promotion of mucosal healing and barrier 
integrity. These contradictory studies poised an important question for 
this IBD-associated molecule: what is the role for TL1A in maintaining 
intestinal homeostasis and how does it contribute to the 
pathophysiology of IBD? By generating novel cell-specific genetic 
deletion models, our data reconcile and offer mechanistic insights into 
the various functions of TL1A during intestinal inflammation. During 
acute colitis, CX3CR1+ MNP-derived TL1A plays an essential role in 
promoting barrier protection and mucosal healing via the regulation of 
ILC3 IL-22. However, during chronic colitis, sustained TL1A signaling 
results in the upregulation of co-stimulatory molecules on ILC3, in 
particular OX40L, which enables ILC3 to directly promote antigen-
specific T cell effector functions, including the propagation of IFN-g-
producing pathogenic T cells leading to increased intestinal tissue 
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damage. These data implicate TL1A as a central regulator of the 
innate and adaptive functions of ILC3 in maintaining intestinal tissue 
homeostasis, but further studies are needed to better therapeutically 
target TL1A in clinical settings. 
6.2  Microbial regulation of CX3CR1+ MNP-derived TL1A 
 Previous studies had identified a role for immune 
complexes/microbial signaling in promoting TL1A production by 
macrophages in vitro42. However, the potential role for commensal 
intestinal microbes in regulating macrophage TL1A had not been 
thoroughly investigated. Here, we identified a key role for intestinal 
bacteria in promoting CX3CR1+ MNP-derived TL1A.  In particular, 
adherent microbiota, including segmented filamentous bacteria (SFB) 
and Adherent-invasive E. coli enriched in Crohn’s disease (AIEC), 
robustly induced TL1A. These findings offer a mechanism by which 
Crohn’s disease-associated microbiota can act acutely to promote 
barrier immunity in wild-type hosts.   
Although signals from the intestinal microbiota were essential 
for TL1A induction during acute colitis, it remains to be explored how 
microbial signals might contribute to TL1A induction during chronic 
colitis. Extrapolation of our acute colitis data suggests that AIEC-
induced TL1A could contribute to the adaptive functions of ILC3 via 
the TL1A-OX40L axis. T cell transfer colitis using AIEC colonized 
germ-free mice with anti-TL1A blocking antibodies would be an 
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interesting experiment to test the hypothesis that adherent intestinal 
microbes contribute to chronic colitis via TL1A induction.  If true, 
targeting specific microbes that robustly induce TL1A, such as IBD-
associated adherent/invasive E. coli, might offer a viable therapeutic 
modality for IBD patients.  
 
6.3  ILC3 as antigen-presenting cells during colitis: a revised 
model 
The discovery of antigen processing and presentation by 
intestinal ILC3 highlights a central role for these cells in linking innate 
and adaptive immunity86.  Although splenic ILC3 can upregulate 
conventional co-stimulatory molecules CD80 and CD86 following IL-
1b stimulation88, the absence of these co-stimulatory molecules on 
intestinal ILC3  at the steady state lead to a model in which they limit 
bacteria-specific inflammatory T-cell responses in the gut89. Here, we 
demonstrate that TL1A stimulation enabled MHCII+ ILC3 to promote antigen-
specific T cell proliferation via MHCII/OX40L co-stimulation in vitro. These 
findings can be extended to our in vivo experiments where we demonstrated 
that ILC3-specific OX40L can promote T cell effector functions in chronic 
colitis models. Our data suggest a revised model in which inducible ILC3 
expression of OX40L co-stimulation may trigger local T cell activation (Figure 
6.1).  
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6.4  Therapeutic Targeting of TL1A 
In IBD patients, there are numerous clinical trials aimed at 
inhibiting the function of TL1A. Our data, and in particular the role for 
TL1A in acute vs chronic colitis, may guide therapeutic targeting of 
TL1A of these patients. Genetic testing has identified protective vs risk 
alleles in TL1A patients47,80,93–95. However, the functional impact of 
these mutations has not been well-characterized, although much can 
be inferred from mouse genetic studies, including our own work. For 
example, TL1A risk alleles that display a loss-of-function phenotype 
might act functionally similar to our acute colitis models, in which 
insufficient MNP-derived TL1A impairs proper wound healing after 
intestinal injury. In this case, treating patients with recombinant TL1A 
might be a viable therapeutic approach. In contrast, patients with the 
risk allele displaying a gain-of-function phenotype might act 
functionally similar to TL1A overexpression models, in which mice 
develop severe intestinal fibrostenosis78. Here, anti-TL1A blocking 
antibodies might improve clinical outcomes. More work in needed, 
however, in characterizing the functional role of these TL1A risk 
alleles in human patients. 
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Figure 6.1. A REVISED MODEL: TL1A is a central regulator of 
Group 3 Innate Lymphoid Cells during colitis. During acute colitis, 
CX3CR1+ MNP-derived TL1A synergizes with IL-23 to promote 
mucosal healing and restoration of barrier integrity. During chronic 
colitis, CX3CR1+ MNP upregulate TL1A which induces OX40L 
expression on ILC3, leading to ILC3 promotion of T cell effector functions. 
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APPENDICES 
 
 
APPENDIX A: Top 100 differentially expressed genes from global 
gene expression profiles of media- or TL1A-stimulated sorted Lin-
CD127+IL23RGFP+ ILC3 from IL23RGFP/WT mice (scatterplot of global 
gene expression presented in Figure 4.1B); baseMeanA (media 
control) and baseMeanB (TL1A stimulated) expression levels 
presented as transcript reads; p-adjusted value < 0.05 after correction 
for multiple hypothesis testing. Genes presented in increasing order of 
p-adj. 
 
Gene ID baseMeanA (Media) 
baseMeanB 
(TL1A stim) log2FoldChange padj 
Ccnd2 1221.14 26657.44 4.45 <1.00E-279 
Csf2 821.48 100424.88 6.93 <1.00E-279 
Egr2 36.39 5998.07 7.36 <1.00E-279 
Icam1 2763.12 69350.99 4.65 <1.00E-279 
Icosl 1128.74 29201.46 4.69 <1.00E-279 
Il22 561.89 83920.99 7.22 <1.00E-279 
Iltifb 48.06 6243.81 7.02 <1.00E-279 
Ip6k3 270.11 8153.72 4.92 <1.00E-279 
Ceacam15 2.26 2664.64 10.2 <1.00E-279 
Cxcl3 83.11 24349.6 8.19 <1.00E-279 
Gzmc 8.23 2753.4 8.39 <1.00E-279 
Ncr1 183.31 5194.1 4.82 1.09E-278 
Adamts15 7649.51 461.87 -4.05 4.25E-251 
Gadd45b 190.19 4600.7 4.6 5.38E-249 
Cxcl16 32.36 4794.66 7.21 3.13E-247 
Ccl5 344.89 6004.73 4.12 2.04E-240 
Tnfsf11 167.4 4137.94 4.63 4.30E-239 
Susd2 51.64 2653.88 5.68 1.91E-234 
Serpinb1a 10666.01 649.05 -4.04 7.22E-234 
Cxcl2 38.52 2366.86 5.94 1.98E-226 
Plat 108.86 3239.27 4.9 3.58E-225 
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Appendix A (continued). 
Gene ID baseMeanA (Media) 
baseMeanB 
(TL1A stim) log2FoldChange padj 
Tagap 649.04 8121.85 3.65 1.19E-222 
Ikbke 1043.47 10932.23 3.39 4.73E-215 
Anxa2 10510.98 81918.85 2.96 1.03E-213 
Tnfsf4 2131.64 18004.7 3.08 8.86E-202 
Ccdc184 3335.25 25894.73 2.96 9.98E-198 
Ehd1 702.87 7467.51 3.41 1.11E-195 
Mrpl38 175.31 3291.37 4.23 3.53E-190 
Plxnd1 584.65 5979.6 3.35 1.62E-177 
Nfkbie 1910.97 14147.59 2.89 5.37E-175 
Idi2 0.91 1147.93 10.3 1.48E-171 
Fas 29.48 1591.18 5.75 7.89E-168 
Nupr1 1674.58 11555.12 2.79 8.07E-158 
Pdgfb 568.77 5384.77 3.24 8.05E-156 
Glipr2 2853.6 17081.98 2.58 1.75E-148 
Lad1 9.56 1135.63 6.89 4.16E-148 
Tnip3 1240.84 8460.19 2.77 2.64E-145 
S100a10 5023.24 26409.43 2.39 6.72E-137 
Xcl1 4.64 954.55 7.69 6.14E-136 
Tgm3 2435.05 54.19 -5.49 1.14E-131 
Bhlhe40 20551.95 97672.42 2.25 1.27E-131 
Blk 1396.83 8510.9 2.61 2.22E-131 
Spry2 2388.2 182.77 -3.71 2.91E-130 
Hsp90b1 7426.31 36333.66 2.29 5.64E-130 
Sqle 952.9 6139.46 2.69 9.04E-126 
Pik3r5 77.37 1565.36 4.34 3.28E-124 
Rac2 11886.99 54375.89 2.19 5.81E-123 
Rcl1 164.75 2076.77 3.66 1.26E-120 
Tuba1a 1483.33 8279.48 2.48 5.28E-120 
Cd74 272.76 5326.01 4.29 8.40E-119 
Rptor 776.3 5041.06 2.7 2.59E-118 
Dennd5a 602.99 4776.82 2.99 2.00E-117 
Olfr175-ps1 2.26 766.97 8.41 9.97E-117 
Gda 83.95 1499.77 4.16 1.39E-114 
Slc2a6 468.63 3507.48 2.9 2.79E-114 
Il2ra 5138.76 23188.83 2.17 8.51E-114 
Rgs2 1669.41 106.02 -3.98 1.17E-113 
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Appendix A (continued). 
Gene ID baseMeanA (Media) 
baseMeanB 
(TL1A stim) log2FoldChange padj 
Il27ra 2429.04 11914.05 2.29 1.45E-113 
Vash1 10.56 862.97 6.35 1.16E-112 
Adap1 73.54 1392.49 4.24 1.40E-111 
Stab1 1927.91 9577.29 2.31 1.75E-110 
Il1r2 49.79 1206.7 4.6 6.24E-110 
Cyp51 1431.97 7515.37 2.39 6.24E-110 
Gpnmb 2193.82 77.08 -4.83 5.04E-109 
Srgn 7290.6 30940.7 2.09 1.92E-108 
Extl1 370.97 2916.39 2.97 2.09E-108 
Traf1 7459.45 42964.76 2.53 3.73E-107 
Fam189b 2631.82 310.53 -3.08 1.05E-106 
Thy1 1733.02 8540.23 2.3 1.95E-106 
Madcam1 0 737.47 #DIV/0! 1.01E-105 
H2-Aa 1675.77 13819.99 3.04 1.87E-105 
Ccl17 44.36 1107.15 4.64 2.85E-104 
Phldb1 67.73 1266.53 4.22 9.93E-104 
Trf 4194 406.78 -3.37 3.44E-103 
Sash3 1333.84 6759.59 2.34 5.80E-103 
Sdc1 1319.63 71.44 -4.21 6.03E-103 
Lpar6 12309.85 2822.35 -2.12 4.05E-100 
Marcksl1 23.79 900.16 5.24 8.02E-100 
Cx3cl1 1952.79 29148.84 3.9 1.29E-99 
Psme2b 3808.53 15741.25 2.05 2.58E-97 
Slc6a7 4623.02 860.76 -2.43 1.09E-95 
Abcc1 3253.16 13481.42 2.05 3.34E-95 
Slc15a3 1475.96 6873.03 2.22 2.40E-94 
Ccdc88a 984.71 5025.37 2.35 5.57E-94 
Pdcd1 5628.86 1018.97 -2.47 2.89E-93 
Nup62 4554.9 17973.28 1.98 3.70E-93 
Ccl22 340.77 2454.13 2.85 1.36E-92 
Slc26a11 749.95 11.62 -6.01 3.18E-92 
Cep164 1759.31 179.9 -3.29 7.94E-92 
Psmb7 1865.31 8100 2.12 7.93E-91 
Pdia6 6077.28 22720.56 1.9 3.64E-89 
Basp1 795.38 4116.53 2.37 2.47E-88 
Meox1 297.15 2184.66 2.88 5.67E-88 
Tnfsf9 244.72 1955.21 3 1.78E-87 
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Appendix A (continued). 
Gene ID baseMeanA (Media) 
baseMeanB 
(TL1A stim) log2FoldChange padj 
Avil 442.45 2751.78 2.64 2.47E-87 
Tnfsf8 1141.18 5248.77 2.2 1.38E-85 
Uap1 255.21 1952.2 2.94 9.44E-85 
Cpne2 3.19 557.52 7.45 2.78E-84 
Slc5a3 316.46 2183.97 2.79 1.48E-83 
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